University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Doctoral Dissertations

Dissertations and Theses

October 2019

Effects of Ivermectin and Perfluorobutanesulfonic Acid (PFBS) on
Lipid Metabolism
Weipeng Qi
University of Massachusetts Amherst

Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2
Part of the Other Food Science Commons

Recommended Citation
Qi, Weipeng, "Effects of Ivermectin and Perfluorobutanesulfonic Acid (PFBS) on Lipid Metabolism" (2019).
Doctoral Dissertations. 1749.
https://doi.org/10.7275/15230818 https://scholarworks.umass.edu/dissertations_2/1749

This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized
administrator of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.

EFFECT OF IVERMECTIN AND PERFLUOROBUTANESULFONIC ACID ON
LIPID METABOLISM

A Dissertation Presented
by
WEIPENG QI

Submitted to the Graduate School of the
University of Massachusetts Amherst in partial fulfillment
of the requirements for the degree of

DOCTOR OF PHILOSOPHY

SEPTEMBER 2019

The Department of Food Science

© Copyright by Weipeng Qi 2019
All Rights Reserved

EFFECT OF IVERMECTIN AND PERFLUOROBUTANESULFONIC ACID ON
LIPID METABOLISM

A Dissertation Presented
by
WEIPENG QI

Approved as to style and content by:

____________________________________
Yeonhwa Park, Chair

____________________________________
John M. Clark, Member

____________________________________
Guodong Zhang, Member

____________________________________
Lili He, Member

__________________________________
Erick A. Decker, Department Head
Department of Food Science

ACKNOWLEDGMENTS
Undertaking this Ph.D. degree has been and will always be one of the most challenging
obstacles in my life, and it would not be possible to do without support from many people.
First, I would like to thank my advisor, Dr. Yeonhwa Park, for being so patient and
always willing to help whenever I need. I see your as my life-time role model for your dedication
to work and your kindness to people.
My sincere thanks go to my dissertation committee members, Dr. John M. Clark, Dr.
Guodong Zhang and Dr. Lili He, for your support and guidance.
Many thanks to all my lab members, past and present: Dr. Yoo Kim, Dr. Xiao Xiao, Dr.
Quancai Sun, Dr. Peiyi Shen, Mr. Tsung-Hsiu Hsieh, Mr. Daniel Colmenares, Dr. Ou Wang, Ms.
Yiren Yue, Dr. Phoebe Chen, Dr. Szu-Hao Yang, Dr. Ye Peng, Mr. Renalison Farias Pereira, Ms.
Jiaying Wang, Ms. Jinning Liu, Ms. Sida Li, Ms. Zhuojia Qian, and Mr. Zhenyu Zhang for your
friendship and help. It has been great sharing the lab with all of you in the past five years.
Thanks also go to all my friends in Amherst for making my life less stressful. I will
always treasure our friendship.
I would like to express my gratitude to my loving family in China for being supportive.
Last but not least, I would thank my wife, Hao Wang, for your understanding and for being such
a great person that help me out when I am emotionally weak throughout my Ph.D. study.

iv

ABSTRACT

EFFECT OF IVERMECTIN AND PERFLUOROBUTANESULFONIC ACID ON
LIPID METABOLISM
September 2019
WEIPENG Qi
B.S., SICHUAN UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Yeonhwa Park
Accumulating evidence has shown a link between environmental contaminants and
altered lipid metabolism. There is currently, however, limited knowledge regarding the causal
molecular mechanisms. Therefore, we investigated the molecular mechanisms of two
environmental contaminants, ivermectin and perfluorobutanesulfonic acid (PFBS), on lipid
metabolism in adipocytes and hepatocytes using cell culture models. We first studied the effects
of ivermectin, an anti-parasitic agent, on the adipogenesis of 3T3-L1 preadipocytes. Our current
results suggest that ivermectin inhibits adipogenesis in 3T3-L1 preadipocytes and the
expression of adipogenic genes where these effects were found to be partially via PPARγdependent, but not FXR-dependent, pathway. Additionally, ivermectin also activates the
expression of glycine receptor subunits, potentially related to the inhibitory effect on
adipogenesis. PFBS is the replacement of perfluorooctanesulfonic acid, which has been
reported to disrupt lipid metabolisms. There is no report, however, of the effect of PFBS on
lipid metabolisms. We found that PFBS treatment extensively promoted the differentiation of
3T3-L1 preadipocytes, resulting in significantly increased TG levels. The effects of PFBS were
found to target the early stage of differentiation, in particular via MEK/ERK-dependent
pathway. The effects of PFBS on hepatic lipid metabolisms were also investigated by using
HepG2 hepatocytes. The current results suggested that PFBS increased the hepatic TG
accumulation when supplemented with fatty acid mixture. The effects were also found mediated
by PPARγ-mediated pathways.
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CHAPTER 1
INTRODUCTION
Previous studies have revealed that environmental factors, other than diet, can be responsible
for the development of metabolic syndromes, which is the clustering of abdominal obesity,
hypertension, dyslipidemia, and type 2 diabetes. Among them, prolonged exposure to
environmental contaminants has attracted more attention as one of the potential causes (Arciello
et al., 2013; Armstrong and Guo, 2019; Patel et al., 2012; Wang et al., 2016). Significant progress
has been made on determining the effect of different kinds of environmental contaminants on
lipid metabolism. However, little is known about the molecular mechanisms by which
environmental contaminants disturb lipid metabolism. Therefore, elucidating the potential role of
environmental contaminants on lipid metabolism, and the underlying mechanisms behind should
provide useful information in developing strategies to prevent and treat related diseases, such as
obesity and type 2 diabetes.
Ivermectin typically consists of a mixture of avermectin B1a and B1b at a ratio of 80:20 and
kills parasites and insects in and on animals and humans primary by interfering with the
glutamate-gated chloride channels, inducing membrane hyperpolarization and paralysis of nerve
and muscle cells (Turner and Schaeffer, 1989). PFBS, the replacement of PFOS since early
2000s, is a four-carbon fluorosurfactant widely used in a wide range of consumer products,
including food packages, fabrics, non-stick products, paints, waxes, cleaners, as well as in some
production facility, including electronics manufacturing, and oil recovery (Favreau et al., 2017;
Herzke et al., 2012). In this proposal, we aimed to determine if ivermectin could alter the
adipogenesis of preadipocytes and if PFBS could impair lipid metabolism in adipocytes and
hepatocytes. The identification of underlying mechanisms of these environmental contaminants
on lipid metabolism is expected to help understanding the role of environmental contaminants in
the development of metabolic diseases associated with lipid metabolism.
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CHAPTER 2
LITERATURE REVIEW
2.1

Introduction
Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are a group of man-made chemicals

that share an aliphatic carbon backbone in which hydrogen atoms have been replaced by fluorine.
In perfluoroalkyl substances, carbon atoms are completely saturated by fluorine; while in
polyfluoroalkyl substances, carbon atoms are mostly replaced by fluorine, and they contain at
least one perfluoroalkyl moiety CnF2(n+1)-, but still contain some carbon-hydrogen bonds. In
both perfluoroalkyl and polyfluoroalkyl substances, the structures are characterized by the high
amount of carbon-fluorine bonds, the forth strongest chemical bond in general and the strongest
bond in organic chemistry (O'Hagan, 2008). With increasing number of fluorine atoms on one
carbon, the bonds become stronger (Lemal, 2004). Due to this structural attribute, PFAS are
generally stable and chemically inert, being able to withstand heat, acids, bases, reducing agents,
oxidants, etc. In addition, the fluorocarbon chain of PFAS is non-polar, and hence highly
hydrophobic. At the same time, this chain is highly lipophobic due to the lower ability to form
instantaneous dipoles that forms the basis of London dispersion force (Lemal, 2004).
Additionally, the sulfate or carboxylate “head” group is hydrophilic, which make PFAS
amphipathic and great materials for use as surfactants. Because of these traits, PFAS, as well as
surfactants and polymers made with the aid of PFAS have been extensively manufactured and
used in a wide range of consumer products, including food packages, fabrics, non-stick products,
paints, waxes, firefighting foam, cleaners, makeup, as well as some production facility, including
electronics manufacturing, and oil recovery since the 1940s (Favreau et al., 2017; Herzke et al.,
2012).
As the result of extensive use, PFAS contaminated the environment through PFAS or
fluoropolymer manufacturing (Emmett et al., 2006; Hoffman et al., 2011; Hu et al., 2016; Hurley
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et al., 2016; Landsteiner et al., 2014; Shin et al., 2011), waste (Allred et al., 2015; Eriksson et al.,
2017; Gallen et al., 2018; Hamid et al., 2018; Lang et al., 2017; Sindiku et al., 2013), aqueous
Film-Forming Foam Concentrates (AFFF) used at airports, military bases and firefighter training
sites (Houtz et al., 2013; Houtz et al., 2016a; Hu et al., 2016), and degradation from precursor
chemicals (Butt et al., 2014; Hagen et al., 1981; Wang et al., 2015; Young and Mabury, 2010).
Drinking water, especially localized with facilities using PFAS, is one of the primary exposure
routes for PFAS. In fact, PFAS can be detected at relatively high concentrations in surface water
all over the world (Post et al., 2012). As most PFAS are extremely stable and hence, relatively
resistant to degradation, which exacerbates their contamination in the environment. Longer chain
PFAS, such as C8 PFAS, have been reported to bioaccumulate in wildlife (Houde et al., 2011).
The bioaccumulation in animal- and plant-based food, as well as the direct contamination from
food packaging, makes food an important route of exposure (Trudel et al., 2008). Alternatively,
air, dust, and direct contact with PFAS-treated products, can also potentiate the exposure of PFAS
to human. In fact, PFAS, especially perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic
acid (PFOA), have been detected in the plasma of human worldwide (Post et al., 2012).
The exposure of PFAS has been extensively reported to induce adverse human health effects on
reproduction (Bach et al., 2016), immune system (Chang et al., 2016), endocrine function (Kim et
al., 2018), kidney function (Conway et al., 2018), cancer (Chang et al., 2014), metabolic diseases
(Christensen et al., 2019), and adverse developmental effects in offspring, such as low birth
weight, high diabetes and obesity risk (Heindel et al., 2017). The concern about potential adverse
effects of PFAS on the environment, wildlife, and humans - especially the long-chain PFAS- led
to the phase-out of perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in
2000s. Alternative shorter-chain PFAS have been developed to replace the long-chain PFAS. In
this review, we summarize the chemistry and historical uses of PFAS and present a systematic
review of the current epidemiology findings on associations between PFAS exposure and the
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development of metabolic syndrome and related diseases including obesity, diabetes, and nonalcoholic fatty liver disease (NAFLD).
2.2

Classification of PFASs
Characterized by their functional groups, PFAS can be divided into numerous families.

This section provides an overview of the common names, chemical structures, and some
important properties and uses of most well-studied PFAS that have been detected in environment
and in humans. The structures for selected PFAS was given in Figure 2.1.

Figure 2.1 Structures of perfluoroalkyl and polyfluoroalkyl substances (PFAS).
2.2.1

Perfluoroalkyl acids
Perfluoroalkyl acids (PFAAs) are the most studied PFASs due to their extensive use in

various industries and their high persistence in both the environment and animal bodies. PFAA
family includes perfluoroalkyl carboxylic, sulfonic, sulfinic, phosphonic, and phosphinic acids.
Perfluoroalkyl carboxylic acids: Perfluoroalkyl carboxylic acids (PFCAs) are a group of
compounds of the formula of CnF(2n+1)COOH. The chemical structures of these compounds
consist of a hydrophilic carboxylate “head group” and a hydrophobic fluorocarbon chain. The
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most studied PFCA is PFOA, C7F15COOH (Figure 1A). PFOA can be synthesized by two major
electrochemical fluorination (ECF) and telomerization. ECF is a technology replacing all the H
atoms in an organic raw material with F atoms by electrolysis in HF (Karsa, 1995; Simons, 1949).
In the early 2000s, a new method was introduced to produce higher percentages of linear products
by oxidizing linear perfluorooctyl iodide (PFOI), F(CF2)8I (Figure 1C), synthesized by
telomerization into PFOA (Ameduri and Boutevin, 2004). PFOA, commonly used as its
ammonium salt ammonium perfluorooctanoate (APFO) produced exclusively by ECF, has been
used as surfactant to solubilize the fluoromonomers in the manufacture of fluoropolymers, for
example polytetrafluoroethylene (PTFE), since 1940s (Ebnesajjad, 2013). Perfluorononanoic acid
(PFNA), C8H17COOH, is another PFCA widely used as the ammonium form in the production of
polyvinylidene fluoride (PVDF) (Schué, 1999). PFNA is produced mainly from the oxidation of
fluorotelomer olefin (Buck et al., 2011).
In the recent decade, production of PFOA and its related precursors has been largely
reduced. In 2006, eight leading manufacturers in PFAS were invited by EPA to join a global
stewardship program aiming to achieve 95% reduction in both emission and product content
levels of PFOA, related higher homologue chemicals and their precursor chemicals by 2010, and
to eliminate these chemicals from emissions and products by 2015.
Besides their major use in fluoropolymer industry, PFCAs are also considered the final
biodegradation product of some precursor PFAS, especially fluorotelomer-based products
including fluorotelomer alcohol, fluorotelomer olefin, fluorotelomer iodides, etc. (Dinglasan et
al., 2004; Frömel and Knepper, 2010; Hagen et al., 1981). It has been estimated, however, ~80%
of PFCAs released to the environment are directly from the fluoropolymer production
(Prevedouros et al., 2006).
Perfluoroalkyl sulfonic acids: Perfluoroalkyl sulfonic acids (PFSAs) are another group of major
PFAAs. Among all the PFSAs, PFOS (Figure 1B), the 8 carbon PFSA, is the most used and wellstudied. Since 1949, the 3M company started to synthesize PFOS by the degradation from
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precursor perfluorooctane sulfonyl fluoride (POSF) produced by ECF, and it can also be
produced by telomerization (Lehmler, 2005). However, PFOS was later detected globally in
wildlife and human, and the biological half-life of PFOS was reported to be 5.4 years (Li et al.,
2018; Olsen et al., 2007). Meanwhile, correlations were reported between serum levels of PFOS
and the development of various diseases (Bach et al., 2016; Chang et al., 2014; Chang et al.,
2016; Heindel et al., 2017; Kim et al., 2018). 3M announced the phase out of C8 based chemicals
in early 2000s. In 2009, PFOS-based compounds were listed in Annex B of the Stockholm
Convention on persistent organic pollutants. Perfluorohexanesulfonic acid (PFHxS), the 8 carbon
PFSA and its salt are also used as a replacement of PFOS. However, the estimated half-life of
PFHxS in human is equivalent to or even longer than PFOS (Li et al., 2018; Olsen et al., 2007).
Thus, PFHxS was added to the candidate list of Substances of Very High Concern (SVHC) in
2007.
Since 2003, 3M started to use perfluorobutanesulfonic acid (PFBS) as a replacement of
PFOS/PFHxS-based chemicals. PFBS is the 4 carbon PFSA, with a half-life in human of about a
month (Olsen et al., 2009b), which is significantly shorter than PFOS and PFHxS. In the last
decade, the levels of PFBS detected in the environment, wildlife and human serum have been
increasing (Glynn et al., 2012; Hölzer et al., 2008; Lam et al., 2016; Ruan et al., 2015; Zhou et
al., 2013b), which poses a concern about the potential adverse effect on public health.
Other perfluoroalkyl acids: Besides PFCAs and PFSAs, environmental occurrence and
detections of perfluoroalkyl sulfinic acids (PFSIAs), perfluoroalkyl phosphonic acids (PFPAs)
and perfluoroalkyl phosphinic acids (PFPIAs) has also been increasingly reported in human
(Ahrens and Ebinghaus, 2010; D'Eon J et al., 2009; Lee and Mabury, 2011). PFSIAs are the
biodegradation products of some precursors chemicals, including N-ethyl perfluorooctane
sulfonamidoethanol (N-EtFOSE) (Boulanger et al., 2005; Rhoads et al., 2008), while PFPAs and
PFPIAs are widely used surfactants in various industries (Howard and Muir, 2010).
.
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2.2.2

Fluorotelomer-based chemicals
Fluorotelomers are a group of oligomers with multiple perfluoroalkyl moieties,

synthesized by telomerization (Ameduri and Boutevin, 2004). Some of these compounds have
recently become of interest as they are recognized as the environmental precursors of PFCAs
(Butt et al., 2014; Dinglasan et al., 2004; Hagen et al., 1981; Young and Mabury, 2010), although
the contribution of these precursors to total exposure to human was reported to be variable among
different PFCAs.
Perfluoroalkyl iodides (PFAIs), also known as Telomer A, are major raw materials in the
production of PFAS-based surfactants by telomerization, with common formula CnF2n+1I. They
are usually obtained by the reaction between a short starting PFAI, the telogen, and
tetrafluoroethylene (CF2=CF2), the taxogen. PFAIs are the most important precursors of
fluorotelomer-based chemicals including fluorotelomer iodides, fluorotelomer alcohol and
fluorotelomer olefin (Lehmler, 2005). By inserting ethylene in the structure, n:2 fluorotelomer
iodides (n:2 FTIs), CnF2n+1CH2CH2I, is obtained. The n:2 FTIs serve as the intermediate products
in the synthesis of the n:2 fluorotelomer alcohols (n:2 FTOHs), as well as certain PFAS. The n:2
fluorotelomer olefins (n:2 FTOs), CnF2n+1CH=CH2, are synthesized by dehydrohalogenation of
n:2 FTIs. As stated above, PFAS, for example PFNA, can be produced by the oxidation of the
respective fluorotelomer olefin. FTOs are also the byproducts of the synthesis of several
fluorotelomer-based chemicals from n:2 FTIs.The n:2 fluorotelomer alcohols (n:2 FTOH),
CnF2n+1CH2CH2OH, are the precursors of their acrylic and methacrylic ester, which can be used to
form fluorinated polymers providing water and oil repellency (Rao and Baker, 1994). These
polymers can be used in textile, paper and leather industry. The phosphoric mono- and di-esters
of FTOH, which are also produced from FTOH, have been used as oil-proof food packaging
(Begley et al., 2008; Yuan et al., 2016). In human, n:2 FTOHs have been reported to be
metabolized into PFCAs (Henderson and Smith, 2007; Martin et al., 2005), which could induce
adverse effects.
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2.3

Sources and pathways of human exposure
Exposure to PFAS can occur through a variety of sources and pathways, including but not

limited to drinking water, food, indoor air and dust. Among them, water contamination is
considered one of the major sources, especially those near certain locations including industrial
sites, military fire training sites, and wastewater treatment plants (Egeghy and Lorber, 2010;
Emmett et al., 2006; Hu et al., 2016; Vestergren and Cousins, 2009). In a US national research
project to determine the contaminants in drinking water, 50% of samples were determined to
contain more than two PFAS, and 72% of detections occurred in ground water samples (Guelfo
and Adamson, 2018). In a US national spatial analysis of PFAS concentrations in drinking water
from 2013-2015, water supplies for 6 million US residents exceed US EPA lifetime advisory
levels for PFOS and PFOA, which is 70 ng/L (Hu et al., 2016). In the last decades, while the
detection levels of long chain PFAS, including PFOS and PFOA, have been declining, alternative
PFAS have been increasingly detected in the drinking water (Houtz et al., 2016; Ruan et al.,
2015; Zhou et al., 2013b).
Dietary intake is another important source of PFAS exposure. According to modeling
studies, PFAS contamination in food accounts for the majority of non-occupational exposure to
PFAS among all the contributing factors (Gebbink et al., 2015; Papadopoulou et al., 2017).
Considering PFAS exposure from all potential exposure routes, Fromme et al. (Fromme et al.,
2009) suggested that food accounts for over 90% of PFOS/PFOA exposure. Recently, more
individual-based daily PFAS intake studies further solidified the conclusion that food is the main
contributor of PFAS in humans (Chen et al., 2018; Haug et al., 2011; Jain, 2018a; Tittlemier et
al., 2006; Tittlemier et al., 2007; Vestergren et al., 2012). According to research comparing
multiple dietary assessment methods, the most abundant individual PFAS in food are PFOA,
PFOS and PFHxS. Among them, PFOS is the main contributor in solid food, while PFOA
contributes the most in liquid food (Papadopoulou et al., 2017). Interestingly, the dietary
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exposure of PFAS is correlated with high consumption of fats, oils, eggs, milk, as well as foods in
paper containers (Tian et al., 2018).
Multiple causes can lead to the contamination of PFAS in food. As PFAS are bioaccumulative and persistent in environment, food derived from animals, in particular seafood,
may contain PFAS due to the exposure of animals to the environment, especially water. Plantbased food can also be contaminated by being watered by PFAS contaminated water. Direct
exposure to food packaging can be another possible cause of contamination, as a great number of
PFAS are widely used in food packaging as oil and/or water repellent, especially in fast food
packaging (Begley et al., 2005; Herzke et al., 2012; Martinez-Moral and Tena, 2012; Poothong et
al., 2012; Tittlemier et al., 2006; Yuan et al., 2016). The migration of PFAS from food packaging
to food has also been extensively reported (Begley et al., 2008; Begley et al., 2005). PFOA
residue in PTFE-coated non-stick cookware could likewise be a potential source of PFAS
exposure through food, although it is generally not considered significant (Schlummer et al.,
2015). Besides these dietary sources, the accumulation of PFAS in human milk, which is the most
important source of PFAS exposure for infants, has also been well-studied, and a growing body
of literature has suggested a link between postnatal exposure to PFAS and health effects in
childhood, adolescence and adulthood (Antignac et al., 2013; Kang et al., 2016; Lee et al., 2018;
Macheka-Tendenguwo et al., 2018; Nyberg et al., 2018; Sundstrom et al., 2011).
In addition to drinking water and food, it has been reported that humans can also be
exposed to PFAS by indoor air, indoor dust, and direct contact with PFAS-treated consumer
products (Fraser et al., 2012; Harrad et al., 2010), which could account for up to 50% of PFAS
exposure in certain individuals (Haug et al., 2011). It has also been suggested that the exposure of
PFAS to pregnant women might also induce exposure of PFAS to embryos and fetus in placenta
during gestation (Apelberg et al., 2007; Fei et al., 2007; Inoue et al., 2004; Midasch et al., 2007).
Along with the trend restricting long chain PFAS production and use in the past decade,
the serum levels of long chain PFAS, including PFOS and PFOA, have been reported to be
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reduced globally, especially in western countries and Japan (Jain, 2018b; Okada et al., 2013;
Olsen et al., 2012; Shu et al., 2019; Tsai et al., 2018). However, the concentration of the
replacements of these long chain PFAS, for example four-carbon PFBS, keep increasing in the
same timeframe (Glynn et al., 2012), which calls for further investigation on their safety.
2.4
2.4.1

Epidemiological evidences
Overweight and obesity
Overall, of the 22 epidemiology studies we found, 15 studies reported positive

associations between overweight or obesity and the exposure to at least one PFAS (Table 2.1).
Among the ten studies that examine obesity/overweight in general populations, at least one PFAS
was found to be associated with increased body mass index (BMI), waist circumference or weight
gain in three cohort studies (Cardenas et al., 2018; Jaacks et al., 2016; Liu et al., 2018a) and three
cross-sectional studies (Christensen et al., 2019; Tian et al., 2019; Yang et al., 2018b) conducted
among general populations in China and US. In these studies, three suggested a positive
association between serum PFOS and overweight or related symptoms (Jaacks et al., 2016; Liu et
al., 2018a; Tian et al., 2019), although a negative association between PFOS and BMI was
reported among German men (Hölzer et al., 2008). Similarly, PFOA was also reported to be
positively associated with increased BMI (Yang et al., 2018b), waist circumference (Tian et al.,
2019), as well as weight re-gain after diet induced weight loss potentially by reducing resting
metabolic rate (Liu et al., 2018a). Positive associations were also reported on other commonly
used PFAS, including PFNA (Christensen et al., 2019; Liu et al., 2018a; Tian et al., 2019; Yang
et al., 2018b), PFHxS (Liu et al., 2018a), and PFDA (Liu et al., 2018a; Tian et al., 2019).
Meanwhile, perfluoroundecanoic acid (PFUnDA), a less studied PFAS, was inversely associated
with the risk of overweight (Christensen et al., 2019). However, four studies in US, Korea and
Germany have shown null association (Blake et al., 2018; Hölzer et al., 2008; Nelson et al., 2010;
Seo et al., 2018).
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Prenatal exposure is another major focus of epidemiology study in overweight or obesity
induction by PFAS. Although the in-utero exposure to PFAS was largely associated with low
birth weight, cohort studies have reported the association between maternal PFAS exposure and
overweight/obesity in childhood and adolescence. Girls born to mother with higher PFOS, PFOA
and PFHxS weighed less when newborn. After 20 months, however, females in the higher
quartile of maternal PFOS concentration were observed to be overweight compared to those in
lower quartile, while no differences in weight were found in PFOA and PFHxS (Maisonet et al.,
2012). Five prospective cohort studies have reported the association between maternal PFAS
exposure and obesity or overweight in children at school age in Europe (Hartman et al., 2017;
Høyer et al., 2015; Lauritzen et al., 2018) and US (Braun et al., 2016; Mora et al., 2016). Among
these studies, two reported positive association limited to female offspring (Hartman et al., 2017;
Mora et al., 2016). Similar results were found in a 20-year follow-up prospective cohort study,
which provides more information for offspring up to young adulthood. The highest quartile of
PFOA concentration in maternal cord blood showed increased risks in higher BMI and waist
circumference in female offspring at age 20 (Halldorsson et al., 2012). However, such
associations cannot be found in male offspring or with other PFAS, including PFOS, PFOSA, and
PFNA (Halldorsson et al., 2012). Therefore, sex might be a potential contributing factor for
PFAS-induced obesity. Despite the positive correlation listed above, several studies reported
inconsistent results on the association between maternal PFAS exposure and obesity. One
prospective study in Netherland reported a non-association between prenatal PFOS/PFOA and
BMI of offspring at 12 months (de Cock et al., 2014). Anderson et al. observed inverse
association between higher PFOS and PFOA maternal exposure and weight and BMI in the first
year (Andersen et al., 2010), although this trend was then diminished when they were at the age
of seven (Andersen et al., 2013).
Adiposity was also found to be associated with PFAS exposure during postnatal and early
childhood. In a perspective birth cohort study in Faroe Islands, the child’s BMI at age 18 months
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and 5 years were associated with maternal postpartum serum concentration of PFOS and PFOA
(Karlsen et al., 2017). However, they only observed weak correlations in PFHxS, PFNA and
PFDA (Karlsen et al., 2017). In another large multicenter prospective cohort study, childhood
exposure to PFOS, but not PFOA, at the age of nine was associated with increase adiposity
markers, including elevated BMI, skinfold thickness and waist circumference, in adolescence and
young adulthood (Domazet et al., 2016).
To summarize, obesity and overweight have been connected to PFAS exposure to general
populations, as well as maternal exposure and childhood exposure. Although null association was
reported in some of these studies, and three studies reported negative associations (Andersen et
al., 2010; Christensen et al., 2019; Hölzer et al., 2008), from the epidemiology data, it may be
sufficient to conclude the positive associations between PFAS exposure and overweight or
obesity.
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Table 2.1 Summary of epidemiology studies of perfluoroalkyl and polyfluoroalkyl substances (PFASs) on risk of obesity or overweight in human.
Study
design
Crosssectional
Cohort

Demographics

N

Summary of results

Ref

German men, mother
and child
Danish mother-child
pairs
US aged 12-80

345

Negative association between serum PFOS and BMI in men

1010

Negative association between maternal PFOS/PFOA and weight at 12 months

2094

No association between serum PFOS/PFOA/PFHxS/PFNA and BMI

Danish mother-child
pairs

665

Cohort

British motherdaughter pairs

447

Cohort

Danish mother-child
pairs
Dutch mother-child
pairs
Greenlandic and
Ukrainian motherchild pairs
US mother-child
pairs
Danish children

811

Positive association between maternal PFOA and increased BMI and waist
circumference of female offspring at 20 years of age; No association in male
offspring
Association between maternal PFOS and PFOA levels and low birth weight;
Positive association between prenatal PFOA and body weight of female
offspring at 20 months
No association between maternal PFOS/PFOA and overweight at 7 years of
age
No association between maternal PFOS/PFOA and weight at 12 months

(Hölzer et al.,
2008)
(Andersen et
al., 2010)
(Nelson et al.,
2010)
(Halldorsson et
al., 2012)

US pregnant women
with BMI< 25 kg/m2
US mother-child
pairs

218

UK mother-daughter
pairs

359

Crosssectional
Cohort

Cohort
Cohort

Cohort
Cohort
Cohort
Cohort

Cohort

148
1022

No association between PFOS/PFOA and overweight; Significant increase in
relative risks of having waist-to-height ratio>0.5 at 5 to 9 years

204

Positive association between maternal PFOA concentration and offspring
adiposity at 8 years of age, and BMI gain from age 2-8
Positive association between serum PFOS at 9 and overweight at 15 and 21

201/202

1006 +
876

Positive association between pre-pregnant serum PFOS and gestational weight
gain
Positive association between maternal PFOS, PFOA, PFNA, and PFHxS and
mid-childhood (median, 7.7 years) overweight in female offspring; No
association in male or early childhood (median, 3.2 years)
Positive association between PFOA and body fat percentage of female
offspring of mothers at middle education level, and negative association for
highest education group; No overall association between maternal PFOS,
PFOA, PFHxS or PFNA and body fat percentage at 9 years of age
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(Maisonet et
al., 2012)
(Andersen et
al., 2013)
(de Cock et al.,
2014)
(Høyer et al.,
2015)
(Braun et al.,
2016)
(Domazet et
al., 2016)
(Jaacks et al.,
2016)
(Mora et al.,
2016)
(Hartman et
al., 2017)

Cohort

Faroese mother-child
pairs

444

Cohort

US adults

210

Positive association between postpartum maternal PFOS/PFOA and
overweight in offspring at 5 years of age; No association in PFHxS, PFNA,
and PFDA
No association between serum levels of 8 PFASs and BMI

Cohort

US adults

957

Positive association between serum PFASs and weight and hip girth

Cohort

Norwegian and
Swedish motherchild pairs
US overweight
adults

412

Positive association between maternal PFOS concentration and increased odds
of child overweight/obesity at 5 years of age

621

Korean adults

786

Positive association between baseline PFOS, PFOA, PFHxS, PFNA and
PFDA and a greater weight re-gain in a diet-induced weight loss setting,
primarily in women
No association between serum levels of 13 PFASs and BMI

Chinese male adults

148

Positive association between serum PFOA/PFNA and increased BMI

US adults

2975

Chinese adults

1612

Positive association between serum PFNA and increased waist circumference;
Negative association between serum PFUnDA and waist circumference
Positive association between serum PFOS, PFOA, PFNA and PFDA and
overweight and waist circumference

Cohort

Crosssectional
Crosssectional
Crosssectional
Crosssectional

(Karlsen et al.,
2017)
(Blake et al.,
2018)
(Cardenas et
al., 2018)
(Lauritzen et
al., 2018)
(Liu et al.,
2018a)
(Seo et al.,
2018)
(Yang et al.,
2018b)
(Christensen et
al., 2019)
(Tian et al.,
2019)

PFOS, perfluorooctanesulfonic acid; PFOA, perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexanesulfonic acid; PFUnDA,
perfluoroundecanoic acid; PFDA, perfluorodecanoic acid
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2.4.2

Diabetes
Among 32 studies we found, 21 reported positive association between PFAS exposure

and prevalence of diabetes (type 2, type 2, and gestational diabetes) or related markers (Table
2.2). Initially, increased standardized mortality rate of diabetes was reported to increase among
workers in polymer production plants, where workers could be exposed to PFOA and APFO
(Leonard et al., 2008). Two reports also observed positive associations with the increase mortality
rate or onset of diabetes (Lundin et al., 2009; Steenland et al., 2015). Ten reports have suggested
that environmental exposure to PFAS was associated with the elevated prevalence of type 2
diabetes (Christensen et al., 2016; He et al., 2018; Lind et al., 2014; Mancini et al., 2018; Su et
al., 2016; Sun et al., 2018), or related biomarkers including area under the curve (AUC) in oral
glucose tolerance test (OGTT), homeostatic model assessment for insulin resistance (HOMA-IR)
index, and fasting glucose (Alderete et al., 2019; Cardenas et al., 2017; Kim et al., 2016b;
Timmermann et al., 2014). However, few studies have found null to inverse relationships; five
reported null associations among US and Canadian adults and children (Fisher et al., 2013;
Karnes et al., 2014; Khalil et al., 2018; MacNeil et al., 2009; Nelson et al., 2010), while inverse
associations were reported by four studies among Taiwanese adults (Su et al., 2016), Swedish
adults (Donat-Vargas et al., 2019), US adults, adolescence and children (Conway et al., 2016;
Koshy et al., 2017), as well as mother and child pairs (Fleisch et al., 2017).
A positive association has also been reported between PFAS exposures and type 1
diabetes. In a case-control study with 44 children and adolescents in Italy, the serum
concentrations of PFOS were significantly higher in patients with type 1 diabetes than in healthy
controls (Predieri et al., 2015), although the significance of this result is limited by its small
sample size. In a larger case-control study among 66,899 participants in C8 Health Project,
however, serum levels of PFOS, PFOA and PFNA were all negatively associated with type 1
diabetes (Conway et al., 2016). Consistent with the finding that PFAS might have protective
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association with type 1 diabetes, PFOS and PFOA exposure have been reported to be positively
associated with improved beta cell function in three different studies in US adults (Cardenas et
al., 2017; Lin et al., 2009; Liu et al., 2018b), although PFNA level was negatively associated with
beta cell function in adolescent (Lin et al., 2009).
PFOS and PFOA exposure was found to be positively associated with gestational
diabetes according to three cohort studies conducted in US, Spain Denmark, and China (Jensen et
al., 2018; Matilla-Santander et al., 2017; Rahman et al., 2019; Wang et al., 2018; Zhang et al.,
2015). Interestingly, in a case control study among Chinese pregnant women, serum levels of
total short chain PFCAs (C4-C7) were positively associated with gestational diabetes (Liu et al.,
2019).
Overall, the epidemiology findings in diabetes are relatively controversial. However,
according to a review summarizing the dose response curves of PFOA in several outcomes, nonmonotonic dose-response curves, even U-shaped dose response curves, were observed in many
studies (Post et al., 2012). Consistently, non-linear relationship can be found in two different
studies in diabetes (Lind et al., 2014; Mancini et al., 2018). Inverse U-shaped relationship
between dietary exposure to PFOA and the risk of developing type 2 diabetes: increasing type 2
diabetes risk at low serum PFOA levels and decreasing risk at high serum PFOA levels (Mancini
et al., 2018). Therefore, the inconsistency might be due to the different exposure levels in
different geological areas in the respective studies, as different PFOA levels might show different
dose responses on diabetes. From the current evidences, PFAS may be positively associated with
type 2 diabetes and gestational diabetes. However, the effects of PFAS on type1 diabetes are not
conclusive, as few epidemiological studies on beta cell function have found a positive association
between PFAS and improved beta cell function.
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Table 2.2 Summary of epidemiology studies of perfluoroalkyl and polyfluoroalkyl substances (PFASs) on risk of altered glucose metabolism in
human.

Study
design
Cohort

Demographics

N

US Dupont workers

6027

Crosssectional

US adolescents and
adults

Cohort

US 3M workers

Crosssectional
Crosssectional
Crosssectional
Crosssectional
Crosssectional
Cohort

US adults
US aged 12-80
Canadian adults
US adults

Summary of results

Ref

Mortality associated with diabetes significantly increases in workers in
polymer production plan
474+969 Negative association between serum PFNA and beta cell function in
adolescents; Positive association between serum PFOS/PFOA and beta
cell function in adults
3993
Mortality associated with diabetes significantly increases in workers in
polymer production plan
13922
No association between serum PFOA and type 2 diabetes prevalence and
fasting glucose
2094
No association between serum PFOS/PFOA/PFHxS/PFNA and HOMAIR
3496
No association between serum PFOS/PFOA/PFHxS and blood insulin,
glucose and HOMA-IR
32254
No association between serum PFOA and type 2 diabetes prevalence
1016

Crosssectional
Cohort

Swedish elderly aged
70
Overweight Danish
children aged 8-10
Italian children aged
2-14
US Dupont workers

499

Non-linear relationship between serum PFNA and type 2 diabetes
prevalence; No association between PFASs and HOMA-IR
Positive association between serum PFOS and blood insulin

44

Positive association between serum PFOS and type 1 diabetes prevalence

3713

Significant positive trend for diabetes onset

Cohort

US pregnant women

258

US male adults aged
> 50
US adults and
children aged > 13

154

Positive association between serum PFOA and gestational diabetes
prevalence
Positive association between serum PFNA/PFUnDA/PFDA and the
prevalence of prediabetes or diabetes
Negative association between serum PFOS/PFOA/PFHxS/PFNA and type
1 and type 2 diabetes

Crosssectional
Crosssectional

66899
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(Leonard et al.,
2008)
(Lin et al., 2009)

(Lundin et al.,
2009)
(MacNeil et al.,
2009)
(Nelson et al.,
2010)
(Fisher et al.,
2013)
(Karnes et al.,
2014)
(Lind et al., 2014)
(Timmermann et
al., 2014)
(Predieri et al.,
2015)
(Steenland et al.,
2015)
(Zhang et al.,
2015)
(Christensen et
al., 2016)
(Conway et al.,
2016)

Cohort

Danish children

201

Doubleblind trial
Crosssectional

Korean elderly aged
> 60
Taiwanese adults

141

Crosssectional
Cohort

US adults with high
diabetes risk
US mother-child
pairs
US adolescents

975
665

Positive association between serum PFOS and diabetes prevalence;
Negative association between PFOA/PFNA/PFUnDA and diabetes
prevalence
Positive association between serum PFOS/PFOA and beta cell function;
Positive association between PFOS/PFOA and HOMA-IR
Negative association between serum PFOA and HOMA-IR

402

Negative association between serum PFHxS and HOMA-IR

Spanish pregnant
women

1204

Positive association between serum PFOA/PFHxS and gestational
diabetes prevalence

Crosssectional
Cohort

US adults

7904

Danish pregnant
women

318

Crosssectional
Crosssectional
Cohort

US obese children
aged 8-12
US adults in
NHANES
French women

48

Case
control
Cohort

US women

29611

Chinese pregnant
women
US overweight
Hispanic youth aged
8-14

560

Positive association between serum PFOA and diabetes prevalence in
male but not in female
Positive association between PFHxS and fasting insulin, fasting glucose
and HOMA-IR in women with high GDM risk; positive association
between PFNA and fasting insulin and HOMA-β in women with high
GDM risk
No association between serum PFOS/PFOA/PFHxS/PFNA and fasting
glucose, insulin and HOMA-IR
Positive association between serum linear PFOA and branched PFOS and
beta cell function
Non-linear relationship between dietary PFOS/PFOA and type 2 diabetes
prevalence
Positive association between plasma PFOS/PFOA and type 2 diabetes
prevalence
Positive association between serum PFOA and HOMA-IR and blood
glucose; Negative association between PFOS and blood glucose
Positive association between serum PFOS/PFOA and fasting glucose;
Positive association between PFHxS and AUC in oral glucose tolerance
test (OGTT)

Crosssectional
Cohort

Cohort

571

Negative association between serum PFOS at 9 and beta cell function at
15
Positive association between serum PFOS/PFDoDA and HOMA-IR index

1871
71270

40
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(Domazet et al.,
2016)
(Kim et al.,
2016b)
(Su et al., 2016)

(Cardenas et al.,
2017)
(Fleisch et al.,
2017)
(Koshy et al.,
2017)
(MatillaSantander et al.,
2017)
(He et al., 2018)
(Jensen et al.,
2018)

(Khalil et al.,
2018)
(Liu et al., 2018b)
(Mancini et al.,
2018)
(Sun et al., 2018)
(Wang et al.,
2018)
(Alderete et al.,
2019)

Case
control
Case
control
Cohort

Swedish adults

248

Negative association between serum PFDA/PFUnDA and HOMA-IR

Chinese pregnant
women
US pregnant women

439

Positive association between serum short chain PFCAs and gestational
diabetes
Positive association between serum PFOA/PFNA /PFHpA/PFDoDA and
gestational diabetes prevalence

2334

(Donat-Vargas et
al., 2019)
(Liu et al., 2019)
(Rahman et al.,
2019)

PFOS, perfluorooctanesulfonic acid; PFOA, perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexanesulfonic acid; PFUnDA,
perfluoroundecanoic acid; PFDA, perfluorodecanoic acid; PFDoDA, perfluorododecanoic acid; PFHpA, perfluoroheptanoic acid.
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2.4.3

Non-alcoholic fatty liver disease
In animals, PFAS have been extensively reported to disrupt hepatic lipid metabolism and

induce non-alcoholic fatty liver disease (NAFLD), which can more specifically be referred to as
Toxicant Associated Fatty Liver Disease (TAFLD) (Wahlang et al., 2012). Proposed mechanisms
include the inhibition of fatty acid beta oxidation, increased fatty acid uptake (Cheng et al., 2016;
Wan et al., 2012), and the induction of oxidative stress (Khansari et al., 2017). In addition, PFAS
exposure is positively associated with increased serum liver enzyme levels of alanine
transaminase (ALT), alkaline phosphatase (ALP) and, γ-glutamyltransferase (GGT) (Darrow et
al., 2016; Gallo et al., 2012; Gleason et al., 2015; Nian et al., 2019; Salihovic et al., 2018;
Yamaguchi et al., 2013), which indicates potential liver damage and leads to steatosis.
Consistently, positive associations were observed between PFHxS/PFOA/PFNA and hepatocyte
apoptosis markers in a report involving 200 adults in Ohio (Bassler et al., 2019), including
Cytokeratin-18 which is also a fatty liver biomarker (Feldstein et al., 2009; He et al., 2017).
However, epidemiology findings on the relationship between PFAS and NAFLD is scarce. The
only report was found in a case control study among an Ohio Valley community, with an elevated
hazard ratio for exposure at a 10-year lag (Darrow et al., 2016). However, this positive
association was based on 36 self-reported cases (Darrow et al., 2016). Two other occupational
studies reported positive trend on non-hepatitis liver disease, but not on NAFLD (Steenland et al.,
2015; Winquist et al., 2013). No direct association between PFAS and NAFLD incidence was
reported. PFAS exposure has been consistently reported to be associated with altered lipid profile
in blood, including increased triglyceride, cholesterol, low density lipoprotein, and reduced high
density lipoprotein (Christensen et al., 2019; Fitz-Simon et al., 2013; Fletcher et al., 2013;
Maisonet et al., 2012). According to a cross-sectional study using NHANES data, participants
with obesity tend to be more susceptible to PFAS-induced dyslipidemia. As NAFLD is well
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associated with obesity, the author suggested that NAFLD might play a role in PFAS-induced
dyslipidemia (Jain and Ducatman, 2019).
In general, epidemiology data on the relationship between PFAS exposure and NAFLD
are largely limited due to the low validation rate of the disease. More well-designed epidemiology
studies are needed to confirm the results from animal studies.
2.5

Conclusion
Accumulating evidences have illustrate the association between PFAS, especially PFCAs

and PFSAs, and the onset or development of metabolic diseases, including obesity, diabetes and
NAFLD. However, inconsistent results can be found in many cases. Therefore, more clinical or
epidemiology studies, especially prospective cohort studies, are needed to confirm the results. It
is also of great significance to investigate the potential mechanism behind these effects using in
vitro and in vivo models, especially for the shorter chain PFAS that have not been well-studied.
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CHAPTER 3
OBJECTIVES OF THE PROJECT
Our long-term goal is to illustrate the causes of the development of obesity and NAFLD, and
to develop prevention and/or treatment strategies. In this proposal, the specific objective is to
clarify the mechanisms of altered lipid metabolism in adipocytes and hepatocytes induced by
environmental contaminants (ivermectin and PFBS). The central hypothesis is that ivermectin can
inhibit adipogenesis of 3T3-L1 preadipocytes; exposure to PFBS can impair lipid metabolism in
adipocytes and hepatocytes, inducing potentiated adipogenesis in adipocytes and fat accumulation
in hepatocytes. The rationale of this proposed research is: by understanding molecular
mechanisms by which exposure to environmental contaminants may induce or prevent the
development of obesity and type 2 diabetes, we will be able to direct more efficient prevention
and/or treatment strategies for these and related pathologies in the future.
Specific Aim 1: Determine the effects and the underlying mechanisms of ivermectin on
adipogenesis in 3T3-L1 adipocytes. The working hypothesis is that ivermectin treatment can
inhibit the differentiation of preadipocytes via PPARγ mediated pathway.
Specific Aim 2: Determine the effects and the underlying mechanisms of PFBS on
adipogenesis in 3T3-L1 adipocytes. The working hypothesis is that PFBS treatment can induce
the differentiation of preadipocytes via MEK/ERK pathway.
Specific Aim 3: Determine the effects and the underlying mechanisms of PFBS on fat
accumulation in HepG2 hepatocytes. The working hypothesis is that PFBS treatment can
induce excessive fat accumulation in HepG2 cells via PPARγ-mediated pathway.
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CHAPTER 4
IVERMECTIN INHIBITS DIFFERENTIATION OF 3T3-L1 PREADIPOCYTES
4.1

Introduction
In the 1970s, a series of 16-membered macrocyclic lactone derivatives, known as

avermectins, were discovered as anti-parasitic agents from the fermentation broth of a soil
actinomycete, Streptomyces avermitilis (Campbell et al., 1983). After its introduction to the
market in 1981, ivermectin, one of the avermectins, soon became the bestselling anti-parasitic
drug, generating annual sales exceeding 1 billion USD worldwide. Currently, ivermectin is still
one of the most widely used anti-parasitic agents against internal and external parasites and
insects, including those that cause onchocerciasis, strongyloidiasis and scabies in humans, and
also for animals, including animals for human consumption.
Ivermectin, typically consists of a mixture of avermectin B1a and B1b at a ratio of 80:20
and kills parasites and insects primary by interfering with the glutamate-gated chloride channels,
inducing membrane hyperpolarization and paralysis of nerve and muscle cells (Turner and
Schaeffer, 1989). Additional ligand-gated chloride channels in mammals (e.g., glycine receptors
(GlyR), gamma aminobutyric acidA (GABAA) receptors) can also be activated by ivermectin,
however, only at substantially higher doses (Adelsberger et al., 2000; Lynagh and Lynch, 2010;
Shan et al., 2001). Ivermectin is believed to be relatively safe to mammals because of the low
effective dose used to control invertebrate pests and the lack of glutamate-gated chloride channels
in mammals. Additionally, ivermectin cannot cross the blood brain barrier due to the efflux by
ABC transporter, which further lower its potential harm to human. In fact, ivermectin is
generally well tolerated at relatively high doses and more frequent regimens in human (Guzzo et
al., 2002) and has displayed a potential in treating non-alcoholic fatty liver disease (NAFLD) and
insulin resistance (Jin et al., 2015). Nevertheless, the potential effects of ivermectin on non-target
tissues, in particular adipose tissue, are often overlooked. Ivermectin is highly hydrophobic with
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an octanol/water coefficient (Kow), an indicator of lipophilicity, of 1,651, suggesting that
ivermectin is a lipophilic, water-insoluble compound (Bloom and Matheson III, 1993).
Consistently, it has been shown that adipose tissue has the highest and the most persistent level of
ivermectin in humans, cattle, goats, etc. (Baraka et al., 1996; Canga et al., 2008; Lanusse et al.,
1997; Lespine et al., 2005). Although ivermectin has 35-day slaughter withdrawal time for cattle
and an 18-day for swine, trace amount of ivermectin have been shown to remain in derived foods
(Crooks et al., 2000; Crooks et al., 1998; Toutain et al., 1988), not to mention problems
associated with the intentional or unintentional misuse of ivermectin (Chicoine et al., 2007). It is
likely that humans have repeated and/or prolonged exposures to ivermectin due to ingestion,
inhalation, and dermal absorption during its administration to animals as well as animal-derived
foods from animals treated with ivermectin, especially in milk and fat (Chicoine et al., 2007;
Toutain et al., 1988). There is a growing body of information reporting a positive correlation
between prolonged exposure to membrane-depolarizing insecticides and altered adipogenesis
(Kim et al., 2016a; Park et al., 2012; Xiao et al., 2017b); (Sun et al., 2017; Sun et al., 2016b; Xiao
et al., 2017a; Xiao et al., 2018). Thus, there is a critical need to understand the role of ivermectin
on human health, especially in adipogenesis. The aim of the present work was therefore to
determine the role of ivermectin in adipogenesis using 3T3-L1 preadipocytes, a cell model most
commonly used for this purpose.
4.2
4.2.1

Materials and Methods
Materials

3T3-L1 preadipocytes were obtained from American Type Culture Collection (Manassas, VA).
Fetal bovine serum (FBS), Dulbecco's modified Eagle's medium (DMEM),
methylisobutylxanthin, human recombinant insulin, dexamethasone (>98% purity), and dimethyl
sulfoxide (DMSO) were purchased from Sigma Aldrich Co. (St. Louis, MO). Ivermectin (>98%
purity, a mixture of 80% 22,23-dihydroavermectin B1a and 20% 22,23-dihydroavermectin B1b)
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was purchased from Alfa Aesar Co. (Ward Hill, MA). Rosiglitazone (>98% purity) was
purchased from Cayman Chemical (Ann Arbor, MI). Z-Guggulsterone (single spot by TLC,
>98% purity) was purchased from Millipore (Bedford, MA). Permethrin (> 98.1% purity, 3phenoxybenzyl (1RS)-cis, trans-3-(2,2-dichlorovinyl) -2,2-dimethylcyclopropanecarboxylate, a
mixture of 38.7% cis and 59.4% trans isomers) and fipronil (> 95% purity, 5-amino-1-(2,6dichloro-alpha,alpha,alpha-trifluoro-p-tolyl)-4-trifluoromethylsulfinylpyrazole-3-carbonitile)
were purchased from Sigma-Aldrich Co. (St. Louis, MO). The amounts of triglyceride and
protein were quantified using Infinity Triglycerides Kit and Pierce BCA Protein Assay Kit,
respectively, both from Thermo Fisher Scientific (Middletown, VA). Trizol and High-Capacity
cDNA Reverse Transcription Kit were purchased from Life Technologies (Carlsbad, CA).
Taqman Universal Master Mix II was obtained from Applied Biosystems (Carlsbad, CA).
Radioimmunoprecipitation assay (RIPA) buffer supplemented with 1% protease inhibitor was
purchased from Boston Bioproducts Inc. (Ashland, MA). Rabbit antibodies against mouse
CCAAT/enhancer-binding protein alpha (C/ EBPα), peroxisome proliferator-activated receptor
gamma (PPAR γ), acetyl-CoA carboxylase (ACC), phospho-extracellular signal-regulated kinases
(pERK), and extracellular signal-regulated kinases (ERK) were purchased from Cell Signaling
Technology (Beverly, MA). Mouse antibodies against mouse β-actin was from Santa Cruz
Biotechnology (Dallas, TX). Goat anti-rabbit and anti-mouse horseradish peroxidase conjugated
secondary antibodies were purchased from Invitrogen (Carlsbad, CA). The ClarityTM Western
ECL Substrate Kit was obtained from Bio-Rad Co. (Hercules, CA).
4.2.2

Cell culture

3T3-L1 preadipocytes were maintained in DMEM supplemented with 10% (v/v) FBS. Two days
after confluence (day 0), preadipocytes were induced for differentiation with DMEM containing
10% FBS and a mixture of methylisobutylxanthine (0.5 mM), dexamethasone (1 mM), and
insulin (1 µg/mL) as described previously (Qi et al., 2018a). At day 2, the medium was switched
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to DMEM with 10% FBS and insulin only. From day 4, insulin was removed from the medium
and cells maintained in DMEM with 10% FBS, changing medium every two days. During
differentiation, cells were treated with ivermectin or with vehicle (DMSO). All treatments
included DMSO at a final concentration of 0.1%.
4.2.3

Measurement of cell viability

Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)-based assay (Gerlier and Thomasset, 1986). 3T3-L1 preadipocytes were seeded in a 96well plate at a density of 5 × 103 cells per well. 2 days after confluence, cells were differentiated
with or without ivermectin at various concentrations for 8 days. The cells were then treated with 5
mg/ml MTT at 37 °C for 4 h. Cell viability was then assessed by the formation of formazan from
MTT. The purple formazan was dissolved in DMSO and the absorbance at 540 nm was
determined using a SpectraMax i3 microplate reader (Molecular Devices, Sunnyvale, CA).
4.2.4

Triglyceride quantification

Triglyceride levels were determined using a commercial kit (Infinity™ Triglycerides Reagent;
Thermo Scientific). Briefly, at day 8, cells were washed twice with phosphate-buffered saline
(PBS) and harvested by scraping the cells from the culture plate in PBS containing 1% Triton-X.
Cell homogenates were obtained by sonication using Fisherbrand™ Model 50 Sonic
Dismembrator (Fisher Scientific), and TG concentrations were determined according to the
manufacturer’s instructions. Protein concentrations were measured using Pierce BCA Protein
Assay Kit (Thermo Scientific) and used for normalization of samples.
4.2.5

Reverse transcriptase quantitative PCR (RT-qPCR) analysis

Total RNA was isolated from cells using TRIzol Reagent (Life Technologies, Carlsbad, CA)
according to manufacturer’s instruction. Conversion of total RNA to single stranded cDNA was
performed using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies,
Carlsbad, CA). Gene expression assays for CCAAT/enhancer-binding protein alpha (C/ EBPα,
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Mm00514283_s1), peroxisome proliferator-activated receptor gamma (PPARγ,
Mm00440940_m1), acetyl-CoA carboxylase (ACC, Mm01304257_m1), fatty acid synthase
(FAS, Mm00662319_m1), fatty acid binding protein 4 (FABP4, Mm00445878_m1), fatty acid
translocase (FAT/CD36, Mm00432403_m1), carnitine palmitoyltransferase 1 alpha (CPT1α,
Mm01231183_m1), glucose transporter 4 (GLUT4, Mm00436615_m1), farnesoid X receptor
(FXR, Mm01240553_m1), CAATT element binding protein beta (C/EBPβ, Mm00843434_s1),
C/EBP homologous protein (CHOP10, Mm00492097_m1), glycine receptor alpha 1 (GlyRα1,
Mm00445061_m1), glycine receptor alpha 2 (GlyRα2, Mm01168376_m1), glycine receptor
alpha 3 (GlyRα3, Mm00475507_m1), glycine receptor alpha 4 (GlyRα4, Mm00501674_m1), and
glycine receptor beta (GlyRβ, Mm00439140_m1), were performed with Taqman Universal
Master Mix II (Applied Biosystems, Carlsbad, CA) on a StepOne Plus Real Time PCR System
(Applied Biosystems, Carlsbad, CA). The results of target gene expression levels were
normalized to the expression level of the eukaryotic18S rRNA gene (Hs99999901_s1) using the
2-ΔΔCt method (Livak and Schmittgen, 2001).
4.2.6

Immunoblotting

Cells were lysed with RIPA buffer supplemented with Protease & Phosphatase Inhibitor Cocktail
(100X, Thermo Scientific, Rockford, IL). Proteins in the cell lysates were separated by
electrophoresis using a 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE).
Electrophoresed proteins were transferred to an Immobilon-P polyvinylidene difluoride
membrane (Millipore, Bedford, MA). After blocking with 5% skim milk for two hours, the
membrane was incubated overnight at 4 °C with primary antibodies at appropriate dilutions.
Horseradish peroxidase conjugated to goat anti-rabbit or anti-mouse IgG was used as the
secondary antibody. Specific proteins were detected using an image Station 4000 MM
(Carestream Health, New Haven, CT) using the ClarityTM Western ECL Substrate Kit (Bio-Rad
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Co., Hercules, CA). β-actin was used as an internal control. Image and results were quantified
with Image J software (NIH).
4.2.7

Data Analysis

Data in Figures 1-5 were analyzed with one-way ANOVA using the Statistical Analysis System
9.3 (SAS Institute, Cary, NC). Data in Figures 6-8 were analyzed with two-way ANOVA. All
data are expressed as the mean ±standard error of the mean (S.E.). Multiple comparisons among
groups were performed using Tukey’s test. P values less than 0.05 are reported as statistically
significant. N is defined as the number of replicates in each experiment.
4.3
4.3.1

Results
Ivermectin inhibited the differentiation of 3T3-L1 preadipocytes
The cytotoxicity of ivermectin on 3T3-L1 preadipocytes was first determined. Cell

viability was not affected by an 8-day exposure to ivermectin at concentrations up to 5 µM
(Figure 4.1). At 10 µM ivermectin, however, significantly reduced cell viability (23% reduction)
was observed when compared to the control (P<0.0001). Based on these results, we used
concentrations at or lower than 5 µM for the following experiments.
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Figure 4.1 Cytotoxicity of ivermectin in 3T3-L1 adipocytes. 3T3-L1 cells in 96-well culture
plates were treated with ivermectin (1.25, 2.5, 5 and 10 µM) for 8 days during differentiation. On
day 8, cell viability was determined by MTT assay. Numbers are mean ±S.E. (n= 10). Means
with different letters are significantly different at P< 0.05.

Next, the effect of ivermectin on triglyceride content was determined. Triglyceride
accumulation was inhibited by ivermectin treatment in a concentration-dependent manner (Figure
4.2). Treatment with either 2.5 µM or 5 µM ivermectin exhibited 58% and 74% reduction in
triglyceride content compared to the control, respectively (P<0.0001).
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Figure 4.2 Ivermectin inhibits triglyceride accumulation in 3T3-L1 cells. After treatment for 8
days, adipocytes were harvested and measured for triglyceride content that were normalized by
protein. Numbers are mean ±S.E. (n=4). Means with different letters are significantly different at
P< 0.05.
4.3.2

Ivermectin inhibited the protein levels of key adipogenic regulators
We further investigated the protein expression levels of key regulators in adipogenesis

and lipogenesis during differentiation period (Figure 4.3). Compared to the control, 5 µM
ivermectin treatment markedly decreased the protein expression of key regulators in adipogenesis
and lipogenesis on day 6 and day 8: peroxisome-proliferator activated receptor gamma (PPARγ,
day 6 - 39% reduction, P=0.0022; day 8 - 45% reduction, P=0.039); CCAAT/enhancer-binding
protein alpha (C/EBPα, day 6- 39% reduction, P=0.018; day 8- 75% reduction, P=0.0036) and
acetyl-CoA carboxylase (ACC, day 6- 35% reduction, P=0.032; day 8- 29% reduction,
P=0.0021).
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Figure 4.3 Effects of ivermectin on protein levels of key molecular mediators of adipogenesis.
Cells were induced to differentiation for 2, 4, 6 and 8 days with or without ivermectin (5 µM)
before harvesting for analysis at day 8. Protein levels of indicated genes were quantified by
western blot analysis. A. Representative results; B. PPARγ, Peroxisome proliferator-activated
receptor gamma; C. C/EBPα, CAATT element binding protein alpha; D. ACC, Acetyl-CoA
carboxylase. Numbers represent mean ±S.E. (n=4). * indicates a significant difference against
the respective control (P< 0.05).
4.3.3

Ivermectin altered the expression of adipogenic genes
Next, we assessed if ivermectin inhibited adipogenesis through the modulation of genes

regulating adipogenic differentiation and lipid metabolism. Figure 4.4A shows the influence of
sustained ivermectin exposure for 8 days on the gene expression levels. Treatment with 5 µM
ivermectin significantly reduced the mRNA levels of the gene encoding the master regulator of
adipogenic differentiation; PPARγ (80% reduction, P=0.0029) as well as its target genes, C/EBPα
(72% reduction, P=0.0004), fatty acid binding protein 4 (FABP4 reduction, 73% reduction,
P=0.0036), and fatty acid translocase (FAT/CD36, 45% reduction, P=0.033) compared to their
respective controls. Consistently, the mRNA expression levels of a key enzymes in de novo fatty
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acid synthesis; fatty acid synthase (FAS, 56% reduction, P=0.0008) and ACC (35% reduction,
P=0.0031) were also suppressed compared to their respective controls. In addition, ivermectin
activated the expression of carnitine palmitoyltransferase 1 alpha (CPT1α, 64% increase,
P=0.050) compared to the control, which is the key enzyme in fatty acid -oxidation. Expression
of glucose transporter 4 (GLUT4, 69% reduction, P=0.0023), a membrane protein that play a
crucial role in insulin mediated glucose uptake, was also suppressed by ivermectin treatment (5
µM) over the control. However, the expression of FXR, which was also known to regulate
adipogenesis, remained unchanged by ivermectin treatment (P=0.8932).
We further determined if ivermectin influence the expression of key adipogenic genes in
the earlier stage of the adipogenesis. C/EBPβ, expresses upon initiation of differentiation and
promotes the expressions of PPARγ and C/EBPα at day 2, was not affected following a 48-hour
treatment with ivermectin (Fig. 4.4B, P=0.5306). However, ivermectin significantly up-regulated
the expression of CHOP10 compared to the control (Figure 4.4B, 168% increase, P=0.0001),
which may lead to suppressed DNA-binding activity of C/EBPβ (Tang and Lane, 2000).
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Figure 4.4 Effects of ivermectin on adipogenic gene expression levels. Cells were induced to
differentiation for 8 days (A) or 2 days (B) with or without ivermectin (5 µM). mRNA levels of
indicated genes were quantified by RT-qPCR and the ∆∆Ct was determined using eukaryotic 18S
rRNA as a housekeeping gene. A. PPARγ, Peroxisome proliferator-activated receptor gamma;
C/EBPα, CAATT element binding protein alpha; FABP4, Fatty acid binding protein 4; CD36,
fatty acid translocase; FAS, Fatty acid synthase; ACC, Acetyl-CoA carboxylase; CPT1α,
carnitine palmitoyltransferase 1 alpha; GLUT4, glucose transporter 4, and FXR, farnesoid X
receptor. B. C/EBPβ, CAATT element binding protein beta; and CHOP10, C/EBP homologous
protein. Numbers are mean ±S.E. (n=3). * indicates a significant difference against the respective
control (P< 0.05).
4.3.4

Ivermectin inhibited fat accumulation by suppressing the middle to late phases of
adipogenesis
To determine the specific adipogenic stages involved in the inhibitory effect of

ivermectin, different exposure periods were evaluated (Figure 4.5). The treatment of ivermectin
during day 2-4, day 0-4, and day 4-8 produced significant reduction in TG content compared to
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the control (day 2-4, 34% reduction, P=0.0003; day 0-4, 37% reduction, P=0.0012; day 4-8, 44%
reduction, P<0.0001). However, treating ivermectin during the first 2 days resulted in no
difference of TG levels compared to the control (Fig. 5, P=0.2808). These results suggest that
ivermectin regulated adipogenic differentiation primarily through suppressing the middle to late
adipogenic stages.
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Figure 4.5 Effects of ivermectin on triglyceride accumulation following different treatment
periods. Cells were exposed to ivermectin (5 µM) during indicated time period and harvested at
day 8. Numbers are mean ±S.E. (n=4). Means with different letters are significantly different at
P<0.05.
4.3.5

Ivermectin inhibits adipogenesis partially by way of a PPARγ-dependent pathway
Based on the observation that ivermectin inhibited adipogenesis likely during the middle

to late stages, we further investigated whether the suppressed adipogenesis caused by ivermectin
is mediated by the inhibition of PPARγ, since PPARγ is one of the most important regulators in
the middle to late adipogenic stage (Chawla et al., 1994; Tontonoz et al., 1995). To determine
whether the effect of ivermectin is PPARγ-mediated, rosiglitazone (an agonist of PPARγ) was
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used to determine if the activation of PPARγ could reverse the inhibition of adipogenesis induced
by ivermectin. Differentiation was induced under the combination treatment of 5 µM ivermectin
and 5 µM rosiglitazone, a potent PPARγ agonist (Hwang et al., 2011; Zebisch et al., 2012). As
shown in Figure 4.6A, there was significant interaction between ivermectin and rosiglitazone
treatment (P=0.0083). As expected, treatment of rosiglitazone alone increased the fat
accumulation by 27% (P=0.0027) and ivermectin significantly reduced the fat accumulation by
70% (P<0.0001) when compared to their respective controls. The fat content of cells treated with
both ivermectin and rosiglitazone, however, were not different from the control but increased
significantly compared to cells treated with ivermectin only (226% increase, P<0.0001), although
still significantly less than rosiglitazone alone (23% reduction with P=0.0011). These results
suggested that ivermectin suppressed fat accumulation, in part, by way of a PPARγ-dependent
pathway.
Figures 4.6B-D shows mRNA expression of regulators of adipogenesis under the cotreatment of ivermectin and rosiglitazone. Interaction can be observed between ivermectin and
rosiglitazone in the expression of PPARγ (P=0.0264), C/EBPα (P=0.0081) and FABP4
(P=0.0038). As expected, rosiglitazone alone significantly increased the expression of PPARγ
(69% increase, P=0.0054), C/EBPα (94% increase, P=0.0037) and FABP4 (94% increase,
P<0.0001) compared to their respective controls. Ivermectin, consistent with the previous data,
significantly inhibited the expression of PPARγ (65% reduction, P=0.0076), C/EBPα (68%
reduction, P=0.028) and, FABP4 (68% reduction, P=0.0006) when compared to the control. The
reduction in gene expression levels induced by ivermectin, however, were abolished by the cotreatment with rosiglitazone (Figures 4.6B-D). These results suggest that PPARγ activation
attenuated the inhibited adipogenesis induced by ivermectin.
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Figure 4.6 Inhibition of triglyceride accumulation and adipogenic gene expression levels caused
by ivermectin were abolished by rosiglitazone. During differentiation, the cells were treated with
ivermectin (5 µM) and rosiglitazone (5 µM). On day 8, (A) triglyceride contents were measured;
(B) gene expression levels were quantified by RT-qPCR and the ∆∆Ct was determined using
eukaryotic 18S rRNA as a housekeeping gene. Numbers are mean ±S.E. (n=4). Means with
different letters are significantly different at P< 0.05.
4.3.6

Ivermectin enhances the expression of glycine receptor subunits
Ivermectin is a known activator of glycine receptor chloride channel (Shan et al., 2001).

Meanwhile, the influx of chloride could cause hyperpolarization (Sharmeen et al., 2010), which
potentially results in altered calcium signals (McCarty et al., 2009) and therefore the inhibition in
the differentiation of adipocytes (Neal and Clipstone, 2002). Thus, here we next investigated the
effects of ivermectin on the expression of the subunits of glycine receptor, which is known to
express in adipocytes (Lopez et al., 2016). As shown in Figure 4.7, ivermectin significantly
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enhanced the expressions of GlyRα3 (123% increase, P=0.0229) and GlyRβ (57% increase,
P=0.021). Therefore, ivermectin activates the expressions of certain subunits of glycine receptor
in 3T3-L1 cells.
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Figure 4.7 Effects of ivermectin on gene expression of glycine receptor subunits. Cells were
induced to differentiation for 8 days with or without ivermectin (5 µM). mRNA levels of
indicated genes were quantified by RT-qPCR and the ∆∆Ct was determined using eukaryotic 18S
rRNA as a housekeeping gene. GlyRα1, glycine receptor alpha 1; GlyRα2, glycine receptor alpha
2; GlyRα3, glycine receptor alpha 3; GlyRα4, glycine receptor alpha 4; GlyRβ, glycine receptor
beta. Numbers are mean ±S.E. (n=3). * indicates a significant difference against the respective
control (P< 0.05).
4.3.7

The inhibitory effect of ivermectin on adipogenesis is FXR-independent
Ivermectin was previously identified as a ligand of FXR in the liver where it

downregulated serum glucose and cholesterol levels by directly targeting FXR (Jin et al., 2013).
In addition, previous in vitro and in vivo studies reported that FXR upregulated adipogenic genes
partially via PPARγ (Abdelkarim et al., 2010; Rizzo et al., 2006). Therefore, we next examined
whether ivermectin influences adipogenesis is FXR-dependent, even though the expression of
FXR was not affected by ivermectin treatment (Figure 4.4A). As shown in Figure 4.8, there was
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interaction between ivermectin and Z-guggulsterone (P=0.0014). Z-gugglesterone, a selective
antagonist of FXR (Urizar et al., 2002), significantly inhibited the triglyceride accumulation
compared to the control (48% reduction, P<0.0001). Ivermectin treatment alone also significantly
reduced triglyceride accumulation (54% reduction, P<0.0001), while the co-treatment of Zguggulsterone and ivermectin further reduced fat content, a 75% reduction compared to Zguggulsterone treated group (P<0.0001). Therefore, combined with the observation that FXR
gene expression was not influenced by ivermectin treatment (Figure 4.4A), we concluded that
FXR is not likely to be involved in the effect of ivermectin on adipogenesis in 3T3-L1.

120

a

TG/Protein
(% of control)

100

80

60

b
b

40

20

c

0

Ivermectin 5 M
Z-Guggulsterone 10 

-

+

-

+

+
+

Figure 4.8 Inhibition of triglyceride accumulation caused by ivermectin was unaffected by FXR
antagonist Z-guggulsterone. During differentiation, the cells were treated with ivermectin (5 µM)
and Z-guggulsterone (10 µM). On day 8, triglyceride contents were measured. Numbers are mean
±S.E. (n=4). Means with different letters are significantly different at P< 0.05.
4.3.8

Ivermectin prevents permethrin- and fipronil-induced adipogenesis
Previously, several membrane depolarizing insecticides, including permethrin and

fipronil, were reported to induce adipogenesis (Kim et al., 2014; Kim et al., 2016a; Park et al.,
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2012; Sun et al., 2016a). Thus, we determined whether the treatment of ivermectin could revert
the adipogenesis induced by these insecticides. From Figure 4.9, permethrin and fipronil
significantly increase the fat content by 54% (P=0.0021) and 21% (P=0.020), respectively,
compared to the control, while ivermectin alone reduced the fat content by 57% (P=0.0005). The
co-treatment of ivermectin with either permethrin or fipronil prevented the increased fat
accumulation caused by these insecticides when administered alone. The co-treatment of
ivermectin with permethrin reduced fat content by 51% compared to permethrin alone
(P=0.0006) and the co-treatment of ivermectin with fipronil reduced fat content by 77%
compared to fipronil alone (P<0.0001).
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Figure 4.9 Treatment of ivermectin significantly reduced fat accumulation induced by permethrin
and fipronil. During differentiation, the cells were treated with ivermectin (5 µM) with or without
permethrin or fipronil (both at 10 µM). On day 8, triglyceride contents were measured. Numbers
are mean ±S.E. (n=3). Means with different letters are significantly different at P< 0.05.
4.4

Discussion
In the current study, we demonstrated that ivermectin treatment inhibited the adipogenesis

of 3T3-L1 preadipocytes. To our knowledge, this is the first report on the correlation between
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ivermectin exposure and adipogenesis. We further illustrated that ivermectin targeted events in
mid- to later stage of adipogenesis, in part, by the down-regulation of PPARγ, which is required
for the maturation of adipocytes (Rosen and MacDougald, 2006).
As most genes that are induced in adipogenesis possess a PPARγ binding site (Siersbæk
et al., 2010), PPARγ is one of the most important transcription factors in the development and the
function of adipocytes. Indeed, the occurrence of high fat diet-induced obesity and insulin
resistance are reduced by the deletion of PPARγ in adipose tissue (Jones et al., 2005) and in
PPARγ-deficient mice (Kadowaki et al., 2002). According to the current results, the effect of
ivermectin on adipogenesis likely occurred in the middle to late stages (day 2-8) of the
differentiation when PPARγ is the key regulator. Treatment with ivermectin during early stage
did not influence the fat content, which further supports a potential key role of PPARγ in the
effect of ivermectin on adipogenesis. Nevertheless, it still remains unclear how ivermectin
suppresses PPARγ and therefore adipogenesis. Previously, it was reported that ivermectin does
not influence the transcriptional activity of PPARγ in COS-7 kidney cells (Jin et al., 2013).
However, it is still possible that ivermectin negatively regulates PPARγ in adipocytes.
C/EBPβ is one of the most well-known upstream regulators of PPARγ (Wu et al., 1995).
C/EBPβ, which is expressed upon the induction of adipocyte differentiation, induces the
expression of PPARγ by binding to its promoter. However, the activation of PPARγ by C/EBPβ
does not occur until 36 hours after induction, as CHOP10 associates with C/EBPβ and fully
suppresses its transcription activity (Tang and Lane, 2000; Tang et al., 2004). At the end of
mitotic clonal expansion (MCE, the two-rounds of cell division in the early stage that is required
for adipogenesis), the expression of CHOP10 declines, completely releasing C/EBPβ from the
CHOP10-dependent constraint, allowing the subsequent transcription of PPARγ and C/EBPα
(Tang and Lane, 1999). In fact, inhibition of C/EBPβ transcriptional activity is essential for the
process of MCE, as the premature expression of PPARγ and C/EBPα prevents MCE (Altiok et
al., 1997; Timchenko et al., 1996; Wang et al., 2001). Although the expression of C/EBPβ was
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reported to be essential for MCE, the CHOP10-induced inhibition of C/EBPβ activity is
independent of MCE (Tang et al., 2003a). In this study, the expression of C/EBPβ was not
affected by the treatment of ivermectin, therefore MCE is likely not involved in the effect of
ivermectin. However, CHOP10 expression was significantly enhanced (Figure 4.4B). Therefore,
it is possible that ivermectin treatment could potentially prevent or delay the downregulation of
CHOP10 without affecting MCE, resulted in inhibited the transcriptional activity of C/EBPβ,
subsequently suppressed the expression of PPARγ and C/EBPα. This possibility is further
supported by the fact that the treatment of ivermectin during early adipogenesis (day 0-2) did not
affect the fat accumulation. Consistently, cell number after 48-hour ivermectin treatment was not
significantly different from control (data not shown). It remains inconclusive, however, whether
ivermectin inhibits the expression of PPARγ via CHOP10 or ivermectin directly affects the
expression of PPARγ.
Ivermectin acts as an activator at mammalian ligand-gated chloride channels
(Adelsberger et al., 2000; Shan et al., 2001). Consistently, with the current data, ivermectin
enhanced the expression of the subunits of glycine receptor chloride channel (Figure 4.7). The
influx of chloride into the cytosol induced by the activation of chloride channels could result in
plasma membrane hyperpolarization (Sharmeen et al., 2010). Hyperpolarization can lead to a
voltage-gated calcium channel-independent calcium influx from media to the cytosol (Konig et
al., 2006; McCarty et al., 2009), which could potentially be associated with ORAI channels
(Trebak and Jr., 2017), and ivermectin has been shown to increase intracellular calcium in
leukemia cells (Sharmeen et al., 2010). The regulation of intracellular calcium levels is essential
for the adipogenesis and lipid metabolism in adipocytes (Shi et al., 2000). The activation of
calcineurin, a calcium-dependent serine/threonine phosphatase, inhibits adipogenesis by
preventing the expression of PPARγ and C/EBPα, but not C/EBPβ (Neal and Clipstone, 2002),
which is in consistent to the current results (Figure 4.4). Indeed, the treatment of glycine receptor
ligand has been reported to decrease high-sucrose-diet induced adiposity in rats (Lopez et al.,
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2016). Interestingly, fipronil, a membrane depolarizing insecticide that blocks GABA-gated
chloride channel and glycine receptor chloride channel, was previously reported to potentiate the
adipogenesis of 3T3-L1 cells (Sun et al., 2016a). Therefore, it is possible that ivermectin could
increase intracellular calcium levels by inducing hyperpolarization, and subsequently activated
calcineurin, which inhibits adipogenesis. Besides CHOP10-mediated and calcineurin-mediated
pathways, PPARγ expression can also be modulated by multiple factors including Early B-cell
factors (EBFs) (Jimenez et al., 2007), Krüppel-like factors (KLFs) (Banerjee et al., 2003; Birsoy
et al., 2008; Mori et al., 2005; Oishi et al., 2005; Pei et al., 2011), sterol regulatory elementbinding protein-1 (SREBP1) (Fajas et al., 1999), zinc finger protein 423 (ZFP423) (Gupta et al.,
2010), nuclear factor I (NFI) (Waki et al., 2011), and GATA-binding factors (Tong et al., 2000).
Further mechanistic study is needed to determine the exact mechanism by which ivermectin
inhibits adipogenesis.
Ivermectin is a known agonist of FXR in the liver and it has been suggested to suppress
hepatic lipogenesis and improve insulin resistance in mice in an FXR-dependent manner (Jin et
al., 2013; Jin et al., 2015; Yang et al., 2019b). Therefore, ivermectin has the potential to be used
to treat non-alcoholic fatty liver disease (Cariou, 2008; Carr and Reid, 2015). The activation of
FXR, however, promotes adipogenic gene expression both in vitro and in vivo in adipose tissue
(Rizzo et al., 2006). Moreover, adipose tissue mass was reduced in FXR-deficient mice, and
mouse embryonic fibroblasts, which were derived from FXR-deficient mice, displayed impaired
adipocyte differentiation, with inhibited expression of PPARγ, C/EBPα and FABP4, as well as
suppressed de novo lipogenesis (Abdelkarim et al., 2010; Cariou et al., 2006). Consistently, Zguggulsterone, an FXR antagonist, inhibited the adipogenesis of 3T3-L1 cells (Yang et al., 2008),
while 6-ethyl-chenodeoxycholic acid, an FXR agonist, promoted adipocyte differentiation in 3T3L1 cells and induced the expression of adipogenic genes in adipose tissue of mice (Rizzo et al.,
2006), although it had no effect on epidydimal fat mass (Cipriani et al., 2010). In the current
study, ivermectin, a known agonist of FXR, inhibited the adipogenesis of 3T3-L1 cells. The

42

current results also showed that the expression of FXR was not induced by ivermectin in
adipocytes (Figure 4.4A). The discrepancy on the effects of ivermectin on FXR in liver and
adipocytes might be due to the difference in the expression levels of FXR. FXR is expressed at a
relatively low level in adipocytes (~50 folds lower than in liver) (Cariou et al., 2006). Moreover,
there might be distinctive tissue specific effects of ivermectin on FXR. With the current data, it
remains inconclusive whether ivermectin influences FXR-induced adipogenesis. However,
because an antagonist of FXR failed to reverse the effect of ivermectin on adipogenesis in 3T3L1 cells, we can conclude that the known role of ivermectin as an agonist of FXR did not play a
role in inhibitory effect of ivermectin in adipogenesis. Because the effect of FXR on adipogenesis
is, in part, dependent on PPARγ (Abdelkarim et al., 2010; Rizzo et al., 2006), the inhibition of
PPARγ by ivermectin might potentially mask the effect of ivermectin-induced FXR activation on
adipogenesis.
The current clinical doses of ivermectin for human parasitic diseases range from 150 to
200 μg/kg body weight (Dourmishev et al., 1998; Youssef et al., 1995). To understand the
absorption, distribution, metabolism and excretion of ivermectin when given at the optimal doses
for human parasitic diseases, a few studies have studied the pharmacokinetic profile of ivermectin
in human. The administration of three subcutaneous doses (200 μg/kg), injected every 2 days
after an oral dose of 200 µg/kg, increased plasma ivermectin levels to 7.9 ng/ml (~9 nM) at 1
week after the last dose (Marty et al., 2005). In 22 patients and 44 healthy volunteers treated with
a single oral dose of 150 µg/kg, the maximal plasma concentration of ivermectin was 52 ng/ml
(~60 nM) (Baraka et al., 1996). Following an oral administration of 12 mg ivermectin-containing
alcoholic solution, the plasma concentration was reported to be 81 ng/ml (~92 nM) (Edwards et
al., 1988). Due to the high hydrophobicity of ivermectin, this compound is widely distributed
within the body, with fat showing the highest and most persistent concentration of 141 ng/g tissue
(~149 nM) after a single oral dose of 150 µg/kg (Baraka et al., 1996). Given this limited data set,
the concentrations used in the current study may not be achievable under these dosing regimens.
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Nonetheless, ivermectin has a broad range of effects and has been used in the treatment of other
human diseases at higher doses. Ivermectin at 10 mg/kg (approximately 11 µM) was reported to
inhibit Wnt-TCF-dependent of human colon cancer (Melotti et al., 2014). Similarly, ivermectin at
3 mg/kg (approximately 3.4 µM) was effective on slowing tumor growth in mice (Sharmeen et
al., 2010). Additionally, ivermectin up to 1.6 mg/kg (approximately 1.8 µM) was previously used
successfully for symptomatic treatment of severe muscle spasticity in human (Costa and
Diazgranados, 1994). Thus, it is possible that repeated exposures to ivermectin may result in its
accumulation in adipose tissue to levels similar to those achieved using the concentrations applied
in the current study, and the significance of the concentrations used in the current study may need
to be carefully evaluated.
4.5

Conclusion
In conclusion, our current study demonstrated the inhibitory effect of ivermectin on

adipogenesis. These results elucidated a potential link between ivermectin exposure and altered
lipid metabolism and adipogenesis. Considering ivermectin is approved for human use and its
safety has been verified by decades of uses, ivermectin can provide a critical insight for the
design of drugs with therapeutic potential against obesity. The current results, however, are
limited to an in vitro model using relatively high concentrations of ivermectin. Further studies in
animals, as well as epidemiology studies, are needed to further evaluate the significance of the
current observations.
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CHAPTER 5
PERFLUOROBUTANESULFONIC ACID (PFBS) POTENTIATES ADIPOGENESIS
OF 3T3-L1 ADIPOCYTES
5.1

Introduction
Per- and polyfluoroalkyl substances (PFASs) are a large group of surface-active

compounds. PFASs, such as perfluorooctanesulfonic acid (PFOS), were extensively used as
water, oil, and stain repellents in food packaging, non-stick cookware, and textiles, for over 50
years. These ubiquitous environmental contaminants are highly persistent in the environment, and
bioaccumulate in living organisms, posing a growing concern for potential adverse effects on
human health (Joensen et al., 2009; Lau et al., 2004; Pérez et al., 2013). Accumulating evidence
reveals a strong correlation between exposure to PFASs and the increased risks for metabolic
syndromes, including obesity (Braun et al., 2016; Halldorsson et al., 2012; Liu et al., 2018a;
Maisonet et al., 2012; Mora et al., 2016).
As a replacement for PFOS, its four-carbon cognate, perfluorobutanesulfonic acid
(PFBS), is widely used due to its shorter biological half-life in humans of ~1 month compared to
that of 5 years for PFOS (Olsen et al., 2007; Olsen et al., 2009a). PFBS is also generated as the
final degradation product from some of the perfluorobutanesulfonyl fluoride-based chemicals
(D'eon et al., 2006). After production and usage for over 15 years, PFBS has become one of the
major perfluorinated environmental contaminants (Skutlarek et al., 2006; Zhou et al., 2013a).
PFBS has been detected in human populations, with increasing concentrations seen in humans
from 2006 to 2010 (Glynn et al., 2012). Similar to PFOS, PFBS was found to distribute to fat
tissue, although the potential adverse effects are largely unknown and understudied (Bogdanska
et al., 2014).
Previously, PFASs, particularly PFOS and perfluorooctanoic acid (PFOA), were reported
to promote adipogenesis in 3T3-L1 adipocytes with increased expression of adipogenic genes,
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including CCAAT/enhancer-binding protein alpha (C/EBPα), peroxisome proliferator-activated
receptor gamma (PPARγ), fatty acid binding protein 4 (FABP4) and lipoprotein lipase (LPL)
(Watkins et al., 2015; Yamamoto et al., 2015). Further, evidence from an animal study revealed
that PFOS administration to mice induced adipogenic gene expression and activated nuclear
factor erythroid 2-related factor 2 (Nrf2) signaling in epididymal white adipose tissue (Xu et al.,
2016). PFASs have also been reported to activate the peroxisome proliferator-activated receptors
(PPARs), PPARα and PPARγ, both in hepatocytes and adipocytes, which play key roles in lipid
metabolism (Rosen et al., 2008; Vanden Heuvel et al., 2006; Zhang et al., 2014). Moreover,
higher plasma concentration of PFASs was associated with the risk of weight gain in human (Liu
et al., 2018a). The effects of PFBS on adipogenesis, however, have not been investigated.
Therefore, we aimed to examine the effects of PFBS exposure on adipogenesis using 3T3-L1
adipocytes.
5.2
5.2.1

Materials and Methods
Materials

3T3-L1 preadipocytes were obtained from American Type Culture Collection (Manassas, VA).
Fetal bovine serum (FBS), Dulbecco's modified Eagle's medium (DMEM),
methylisobutylxanthin, human recombinant insulin, dexamethasone, dimethyl sulfoxide (DMSO),
and Perfluorobutanesulfonic Acid (PFBS, 97%) were purchased from Sigma Aldrich Co. (St.
Louis, MO). The amounts of triglyceride and protein were quantified using Infinity triglycerides
kit and Pierce BCA protein assay kit, respectively, both from Thermo Fisher Scientifics
(Middletown, VA). Trizol and High-Capacity cDNA Reverse Transcription Kit were purchased
from Life Technologies (Carlsbad, CA). Taqman Universal Master Mix II was obtained from
Applied Biosystems (Carlsbad, CA). Radioimmunoprecipitation assay (RIPA) buffer
supplemented with 1% protease inhibitor was purchased from Boston Bioproducts Inc. (Ashland,
MA). Rabbit anti-CCAAT/enhancer-binding protein alpha (C/ EBPα), anti-peroxisome
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proliferator-activated receptor gamma (PPAR γ), anti-acetyl-CoA carboxylase (ACC), antiphosphor-p42/p44 (pERK), and anti-p42/p44 (ERK) were purchased from Cell Signaling
Technology (Beverly, MA). Mouse anti-β-actin was from Santa Cruz Biotechnology (Dallas,
TX). Goat anti-rabbit and anti-mouse horseradish peroxidase conjugated secondary antibodies
were purchased from Invitrogen (Carlsbad, CA). The ClarityTM Western ECL Substrate Kit was
obtained from Bio-Rad Co. (Hercules, CA).
5.2.2

Cell culture

3T3-L1 preadipocytes were maintained in DMEM supplemented with 10% (v/v) FBS. Two days
after confluence (day 0), preadipocytes were induced for differentiation with DMEM containing
10% FBS and a mixture of methylisobutylxanthin (0.5 mM), dexamethasone (1 mM), and insulin
(1 µg/mL), as described previously (Sun et al., 2016a). At day 2, the medium was switched to
DMEM with 10% FBS and insulin only. From day 4, insulin was removed from the medium and
cells maintained in DMEM with 10% FBS, changing medium every two days. During
differentiation, cells were treated with PFBS at increasing concentrations or with vehicle
(dimethylsulfoxide, DMSO). All treatments included DMSO at a final concentration of 0.1%.
5.2.3

Measurement of cell viability

Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)-based assay (Gerlier and Thomasset, 1986). 3T3-L1 preadipocytes were seeded in a 96well plate at a density of 5 × 103 cells per well. 2 days after confluence, cells were exposed to
PFBS for 6 days. The cells were then treated with 5 mg/ml MTT at 37 °C for 4 h. After
incubation, MTT-formazan was dissolved in DMSO and the absorbance at 540 nm was
determined using a SpectraMax i3 microplate reader (Molecular Devices, Sunnyvale, CA).
5.2.4

Triglyceride quantification

Triglyceride (TG) levels were determined using a commercial kit (Infinity™ Triglycerides
Reagent; Thermo Scientific). Briefly, at day 6 cells were washed twice with phosphate-buffered
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saline (PBS) and harvested by scraping the cells from the culture plate in PBS containing 1%
Triton-X. Cell homogenates were obtained by sonication and TG concentrations were determined
uisng the commercial kit according to the manufacturer’s instructions. Protein concentrations
were measured using Pierce BCA protein assay kit (Thermo Scientific) and used for
normalization of samples.
5.2.5

Reverse Transcriptase quantitative PCR (RT-q-PCR) analysis

Total RNA was isolated from cells using TRIzol Reagent (Life technologies, Carlsbad, CA)
according to manufacturer’s instruction. Conversion of total RNA to single stranded cDNA was
performed using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies,
Carlsbad, CA). Gene expression assays for CCAAT/enhancer-binding protein a (C/ EBPα,
Mm00514283_s1), peroxisome proliferator-activated receptor gamma (PPARγ,
Mm00440940_m1), acetyl-CoA carboxylase (ACC, Mm01304257_m1), fatty acid synthase
(FAS, Mm00662319_m1), and fatty acid binding protein 4 (FABP4, Mm00445878_m1) were
performed with Taqman Universal Master Mix II (Applied Biosystems, Carlsbad, CA) on a
StepOne Plus real time PCR instrument (Applied Biosystems, Carlsbad, CA). The results of
target gene expression levels were normalized to the expression level of the18S rRNA
gene(Hs99999901_s1) using the 2-ΔΔCt method (Livak and Schmittgen, 2001).
5.2.6

Immunoblotting

Cells were lysed with RIPA buffer supplemented with Protease & Phosphatase Inhibitor Cocktail
(100X, Thermo Scientific, Rockford, IL). Proteins in the cell lysates were separated by
electrophoresis using a 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE).
Electrophoresed proteins were transferred to an Immobilon-P polyvinylidene difluoride
membrane (Millipore, Bedford, MA). After blocking with 5% skim milk for two hours, the
membrane was incubated overnight under 4 °C with primary antibodies at appropriate dilutions.
Horseradish peroxidase conjugated goat anti-rabbit or anti-mouse IgG was used as the secondary
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antibody. Specific proteins were detected using an image Station 4000 MM (Carestream Health,
New Haven, CT) using the ClarityTM Western ECL Substrate Kit (Bio-Rad Co., Hercules, CA).
GAPDH or β-actin was used as an internal control. Image and results were quantified with Image
J software (NIH).
5.2.7

Cell counting

After exposure to PFBS (0, 10, 50, 100 μM) for 48 hours, cells were trypsinized and collected by
centrifugation at 1000g for 5 minutes. Cell suspension was then subjected to cell counting with
hemocytometer (Fisher Scientific, Horsham, PA).
5.2.8

Data Analysis

Data in figure 1-6 were analyzed with one-way ANOVA using the Statistical Analysis System
(SAS Institute, Cary, NC). Data in figure 7 were analyzed with two-way ANOVA. All data are
expressed as the mean ±standard error of the mean (S.E.). Multiple comparisons among groups
were performed using Tukey’s test. P values less than 0.05 are reported as statistically significant.
N is defined as the number of replicates in each experiment.
5.3
5.3.1

Results
PFBS enhances fat accumulation in 3T3-L1 cells
PFBS had no effect on cell viability at concentrations up to 200 µM after a 6-day

exposure (Figure 5.1). PFBS treatment during adipogenic differentiation significantly promoted
lipid accumulation in a dose dependent manner compared with the DMSO control (Figure 5.2).
Cells treated with 200 µM PFBS showed a 35% increase in triglyceride content compared to the
control (P<0.0001). Treatments of 50 µM and 100 µM PFBS also significantly elevated TG
levels above the control (21% and 25% increases, respectively). From these results, it was
decided to use PFBS concentrations up to 100 µM for the following experiments.
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Figure 5.1 Cytotoxicity of PFBS in 3T3-L1 adipocytes. 3T3-L1 cells in 96-well culture plates
were treated with PFBS (12.5, 25, 50, 100, and 200 µM) for 6 days during differentiation. On day
6, cell viability was determined by MTT assay. Numbers are mean ±S.E. (n= 10). Means with
different letters are significantly different at P< 0.05.
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Figure 5.2 PFBS promotes triglyceride accumulation in 3T3-L1 cells. After treatment for 6 days,
adipocytes were harvested and measured for triglyceride content that were normalized by protein.
Numbers are mean ±S.E. (n=4). Means with different letters are significantly different at P<
0.05.
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5.3.2

PFBS upregulates the expression of adipogenic genes
Next, we assessed whether PFBS potentiated adipogenesis through the upregulation of

genes known to be involved in adipogenic differentiation and/or lipid metabolism. Treatment
with 100 µM PFBS for 6 days significantly increased the mRNA levels of genes encoding two
master regulators of adipogenic differentiation; CCAAT/enhancer-binding protein alpha
(C/EBPα, 84%, P=0.0047) and peroxisome-proliferator activated receptor gamma (PPARγ, 29%,
P<0.0001), as well as their target gene fatty acid binding protein 4 (FABP4, 159%, P<0.0001)
(Figure 5.2) when compared with the control. The mRNA expression level of key regulatory
enzymes involved in de novo lipogenesis; fatty acid synthase (FAS, 84%, P<0.0001) and acetylCoA carboxylase (ACC, 37%, P=0.0049), were also significantly increased by 100 µM PFBS
treatments compared with the control (Figure 5.3). Likewise, 100 µM PFBS treatments also
significantly increased the protein expression levels of PPARγ and C/EBPα compared with the
control by 76% (P=0.006) and 77% (P=0.0017), respectively (Figure 5.4 B and C). In a similar
manner, the protein expression of ACC was also increased by PFBS (69%, P=0.0021, Figure 5.4
D) compared to the control.
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Figure 5.3 Effects of PFBS on adipogenic gene expression. Cells were induced to differentiation
for 6 days with or without PFBS (10, 50, 100 µM). mRNA levels of indicated genes were
quantified by real-time PCR and the ddCt was determined using 18S RNA as a housekeeping
gene. C/EBPα, CAATT element binding protein alpha; PPARγ, Peroxisome proliferator-activated
receptor gamma; FAS, Fatty acid synthase; ACC, Acetyl-CoA carboxylase; and FABP4, Fatty
acid binding protein 4. Numbers are mean ±S.E. (n=3). Means with different letters are
significantly different at P< 0.05.
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Figure 5.4 Effects of PFBS on protein levels of molecular mediators of adipogenesis. Cells were
induced to differentiation for 6 days with or without PFBS (10, 50, 100 µM). Protein levels of
indicated genes were quantified by Western blot. A. Representative results; B. PPARγ,
Peroxisome proliferator-activated receptor gamma; C. C/EBPα, CAATT element binding protein
alpha; D. ACC, Acetyl-CoA carboxylase. Numbers represent mean ±S.E. (n=3). Means with
different letters were significantly different at P< 0.05.
5.3.3

PFBS potentiates fat accumulation by targeting early phase of adipogenesis
To determine the specific adipogenic developmental stage targeted by PFBS, we next

examined the effect of PFBS on lipid accumulation at different exposure intervals. A significant
increase in lipid accumulation was observed in cells treated with PFBS at day 0-2 (P=0.0078),
day 0-4 (P=0.0020) and day 0-6 (P<0.0001), while treatment after day 2 showed no effect
compared to the control (Figure 5.5). It is apparent that longer treatment of PFBS potentiated fat
accumulation (from day 0 to 2-6 days). These finding suggested that PFBS induced adipogenesis,
particularly targeting events in early adipogenesis.
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Figure 5.5 Effects of PFBS on fat accumulation with different treatment periods. Cells were
exposed to PFBS (100 µM) on indicated time period and harvested at day 6. Numbers are mean ±
S.E. (n=4). Means with different letters are significantly different at P<0.05.
5.3.4

PFBS activates mitotic clonal expansion
Upon exposure to adipogenic inducers, such as methylisobutylxanthin, dexamethasone,

and insulin, growth-arrested preadipocytes re-enter the cell cycle and undergo two rounds of cell
division in the subsequent 2 days, a process called mitotic clonal expansion (MCE). MCE is a
prerequisite for the expression of adipogenic genes that produce the terminal differentiated
phenotype. As observed in Figure 5, the effect of PFBS targets the early stage of differentiation in
3T3-L1 cells when MCE is triggered. Therefore, we next examined whether MCE was affected
by PFBS. Treatments with PFBS (50 & 100 µM) for 48 h significantly increased the relative cell
number compared to the control by 13% (P=0.0076) and 20% (P=0.0005) compared to the
control, respectively, which implied the activation of MCE by PFBS treatment (Figure 5.6).
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Figure 5.6 Activation of mitotic clonal expansion in preadipocytes by PFBS. Upon induction of
differentiation, preadipocytes were treated by PFBS (10, 50 and 100 µM) for 48 hours. Then, cell
numbers were determined by hemocytometer. Numbers are mean ±S.E. (n=6). Means with
different letters are significantly different at P< 0.05.
5.3.5

PFBS induces adipogenesis via MEK/ERK pathway
The activation of ERK is one of the crucial steps in the early stages of adipogenesis. The

inhibition of ERK phosphorylation during the early adipogenesis has been shown to significantly
inhibit fat accumulation in the later stages (Prusty et al., 2002). Also, ERK activation was
reported to be essential to MCE. Therefore, we next determine whether the effect of PFBS was
dependent on the activation of ERK. The treatment of PFBS (100 μM) for 4 hours significantly
increased the ratio of pERK and ERK by 38% compared to the control (Figure 5.7, P=0.047).
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Figure 5.7 Activation of ERK pathway by PFBS. Upon induction of differentiation, preadipocytes
were treated by PFBS (100 µM) for 4 hours. Then, phosphorylation of ERK was determined by
immunoblotting. A. Representative results; B. Ratio of phospho-ERK to ERK. Numbers are mean
±S.E. (n=3). * indicates a significant difference against the control (P< 0.05).
To further confirm if the enhanced adipogenesis by PFBS is mediated by ERK activation,
we next co-treated the cells with PFBS (100 μM) and U0126 (50 μM), a specific MEK/ERK
pathway blocker, for 6 days. PFBS significantly increased fat accumulation consistent with the
results shown in Fig. 1 (P<0.0001), while U0126 treatment alone did not change the fat content.
However, the increased fat accumulation induced by PFBS was abolished with co-treatment of
U0126 (Figure 5.8). These results suggested that PFBS increased fat accumulation, in part, via a
MEK/ERK-dependent manner.
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Figure 5.8 Activation of ERK with PFBS was abolished by MEK1/2 specific inhibitor U0126.
During differentiation, the cells were treated with PFBS (100 µM) and U0126 (50 µM). On day 6,
triglyceride contents were measured. Numbers are mean ±S.E. (n=4). Means with different
letters are significantly different at P< 0.05.
5.4

Discussion
In this study, we demonstrated that PFBS exposure contributes to increased adipogenesis

of 3T3-L1 adipocytes. To our knowledge, this is the first report on the correlation between PFBS
exposure and adipogenesis. Further, we found that the effect of PFBS on adipogenesis occurs
primarily during early stage of adipogenesis, and mitotic clonal expansion (MCE) is induced by
PFBS treatment during this developmental interval. The current results also suggest that PFBS
influence adipogenesis, in part, via the up regulation of the MEK/ERK-dependent pathway,
which affects MCE in the early stages of adipogenesis that is a crucial step of adipogenesis and
the activation of this step has been reported to induce adipogenesis (Tang et al., 2003b).
ERK1/2 are activated by phosphorylation of threonine and tyrosine residues by the dual
specificity kinase MAPK/ERK kinase 1/2 (MEK1/2), which is essential to the induction of MCE
and the subsequent adipogenesis (Bost et al., 2005; Qiu et al., 2001). The activation of this
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pathway during early adipogenesis promotes adipogenesis by activating the transcription factors
to initiate the expression of PPARγ and C/EBPα. Conversely, the inhibition of MEK/ERK
pathway by U0126 has been suggested to inhibit adipogenesis (Prusty et al., 2002). Our results
suggest that the effect of PFBS on increase adipogenesis is in part dependent on the activation of
the MEK/ERK pathway. Thus, PFBS appears to initially activate the MEK/ERK pathway, which
further induces an accelerated MCE, showing increase in cell number after 48-hour treatment.
Other PFASs, including PFOS, have been reported to increase cell number of 3T3-L1 cells
(Watkins et al., 2015), and PFOS activates ERK in multiple cell lines, including HAPI microglial
cells and cerebellar granule cells (Lee et al., 2013; Wang et al., 2015), which are consistent to the
current results. Similar effects were likewise observed following treatments with PFOA or
perfluorohexanesulfonic acid (PFHxS) (Lee et al., 2014; Upham et al., 2009). Therefore, we
speculate that other PFASs might share common mechanism for adipogenesis as PFBS. However,
this is the first to report on the role of PFBS in adipogenesis.
It is not clear how PFBS activates ERK in the current study, however, previously it was
reported that PFOS and PFOA elevate cytoplasmic calcium levels by releasing calcium ions from
intracellular calcium stores (Liu et al., 2011), where elevated calcium levels can subsequently
activate ERK through calmodulin kinase I (CaMKI) (Chuderland and Seger, 2008; Schmitt et al.,
2004). Alternatively, elevated calcium levels can activate phospholipase C and protein kinase C,
leading to ERK activation (Huang, 1989; Orton et al., 2005). Further studies are needed to
determine if PFBS activates ERK via modulating calcium levels.
PFBS is generally believed to be less toxic than PFOS due to its shorter biological halflife of a month in comparison to 5.4 years for PFOS (Olsen et al., 2007; Olsen et al., 2009a). In
our study, PFOS treatment had no effect on adipogenesis (Supplementary Figure S2). This is
consistent with a previous study reporting no effect of PFOS on adipocyte differentiation in 3T3L1 adipocytes (Yamamoto et al., 2015). Others reported that PFOS was less potent than
perfluorohexane sulfonate (PFHxS), a short-chain cognate of PFOS, in adipogenesis (Watkins et
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al., 2015; Xu et al., 2016). Even though PFBS is more potent in adipogenesis than PFOS, tissue
levels of PFBS are relatively low compared to other PFASs: 5-40 fold lower than that of PFOS
(Bogdanska et al., 2014). However, it is reported that PFBS and PFOS have similar tissue
distribution (Bogdanska et al., 2014) and the concentration of PFBS in humans currently is rising.
Thus, more attention should be paid to the potential effects of long-term exposure of PFBS as
well as interactions with other PFASs including PFOS on adipogenesis.
A few studies have examined the concentration of PFBS in humans or animals and have
led to a 7 μg/L (23 nM) health risk limit for ground water established in Minnesota, and the EPA
has set a subchronic reference dose of 0.2 mg/kg/d and chronic reference dose of 0.02 mg/kg/d
(EPA, 2014). In a 90-day oral administration study on rats, the no-observed-adverse-effect level
(NOAEL) for PFBS was set at 60 mg/kg/d for males and 600 mg/kg/d for females (Lieder et al.,
2009). In a pharmacokinetic study following the exposure to 16 mg/kg/d of 35S-labeled PFBS, 35S
labeled PFBS was found to distribute to epididymal fat and blood at 5 μmol/kg and 19 μmol/kg
(~19 μM), respectively (Bogdanska et al., 2014). Serum PFBS levels of factory workers have
been found to be approximately 23 ng/ml (77 nM) (Fu et al., 2015). Given this limited data set,
the doses used in the current study may not be achievable. Nevertheless, the effects of obesogens
can be aggravated by dietary fat as previous studies have shown the interaction between
obesogens and dietary fat (Sun et al., 2017; Sun et al., 2016b; Xiao et al., 2015; Xiao et al., 2018).
5.5

Conclusions
To summarize, our current study reports the effects of PFBS, the replacement compound

for PFOS, on adipogenesis. These results are significant in elucidating a potential link between
the risk of developing obesity and the exposure to the replacement of PFOS, which is a known
obesogens. However, the current results are limited to an in vitro model using relatively high
concentrations of PFBS. Further studies in animals, as well as epidemiology studies, are needed
to further confirm our in vitro results.
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CHAPTER 6
Perfluorobutanesulfonic Acid (PFBS) induces fat accumulation in HepG2 liver cells
6.1

Introduction
Nonalcoholic fatty liver disease (NAFLD) is the excessive accumulation of fat in liver

without routine alcohol intake, which is considered one of the most prevalent chronic liver
diseases (Younossi et al., 2016). The surpassed storage of fat disrupts normal hepatic lipid
metabolism, and contributes to a number of metabolic syndromes, including dyslipidemia,
hypertension, and type 2 diabetes. In recent decades, it has been reported that the exposure to
environmental contaminants could be positively associated with the development of NAFLD
(Arciello et al., 2013; Armstrong and Guo, 2019).
Perfluoroalkyl substances (PFAS) are a large group of surface-active compounds. PFAS,
especially PFOS, have been extensively used as water, oil, and stain repellents in food packaging,
non-stick cookware, textile, etc. for over 50 years, which makes them among the most ubiquitous
environmental contaminants (Boulanger et al., 2005; Hoffman et al., 2011; Post et al., 2012).
These compounds are relatively stable (Lemal, 2004), highly persistent in the environment (Li et
al., 2018), and tend to accumulate in living organisms, causing a growing concern for their
potential adverse effects on human health. In fact, accumulating evidence has revealed the
correlation between the exposure to PFAS and the increased risks for metabolic syndromes,
including NAFLD (Das et al., 2017), which has led to regulatory restrictions on their usages. As a
replacement for PFOS, its four-carbon cognate, PFBS, was widely used due to the shorter
biological half-life since early 2000s (Olsen et al., 2009a). PFBS is also expected to be the final
degradation product from some of the perfluorobutanesulfonyl fluoride-based chemicals (D'eon et
al., 2006). After production and usage for over 15 years, PFBS has become a growing concern.
PFBS has been detected in the human serum, with an increase in PFBS level in humans during
2006-2010 (Glynn et al., 2012). Similar to PFOS, PFBS was found to distribute to the liver
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(Bogdanska et al., 2014; Olsen et al., 2009a), where it is metabolized, although the potential
adverse effects are largely unknown. However, slight increases in liver weight and hepatocellular
hypertrophy were reported in rats exposed to high doses of PFBS (300 and 1000 mg/kg/day) for
70 days (Lieder et al., 2009). Besides, PFBS was reported to induce adipogenesis in 3T3-L1 cells
(Qi et al., 2018b), suggesting a potential disruption on lipid metabolisms. In addition, PFAS have
been reported to disrupt lipogenesis (Zhang et al., 2019), fatty acid uptake (Huck et al., 2018),
fatty acid β oxidation (Wan et al., 2012), reactive oxygen species (ROS) generation (Qian et al.,
2010), endoplasmic reticulum (ER) stress (Oh et al., 2017), and calcium homeostasis (Liu et al.,
2011), which are related to the hepatic TG accumulation. Thus, the aim of the current work was
to determine the role of PFBS in hepatic lipid metabolism, as well as the potential mechanisms
behind the effects, using HepG2 cell as a model system.
6.2
6.2.1

Material and Methods
Materials

HepG2 human hepatocytes were obtained from American Type Culture Collection (Manassas,
VA). Fetal bovine serum (FBS), Dulbecco's modified Eagle's medium (DMEM), bovine serum
albumin (BSA, >98%), dimethyl sulfoxide (DMSO), and perfluorobutanesulfonic acid (PFBS,
97%) were purchased from Sigma Aldrich Co. (St. Louis, MO). Penicillin streptomycin (100X)
solution was purchased from GE Healthcare Life Sciences (Uppsala, Sweden). Palmitic acid (>
99%) and oleic acid (>99%) was from Nu-Chek Prep, Inc. (Elysian, MN). 3-(4,5Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Biosynth
International (Itasca, IL). The amounts of triglyceride and protein were quantified using Infinity
triglycerides kit and Pierce BCA protein assay kit, respectively, both from Thermo Fisher
Scientifics (Middletown, VA). Trizol and High-Capacity cDNA Reverse Transcription Kit were
purchased from Life Technologies (Carlsbad, CA). Taqman Universal Master Mix II was
obtained from Applied Biosystems (Carlsbad, CA). 2′,7′-Dichlorofluorescin diacetate (DCFDA,
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>95%) and GW9662 (>98%) was purchased from Cayman Chemical (Ann Arbor, MI). Fura-2acetoxymethyl ester (Fura-2 AM, >95%) was purchased from Abcam (Cambridge, MA).
6.2.2

Cell culture

HepG2 cells were maintained in DMEM supplemented with 10% (v/v) FBS, 10,000
U/mL penicillin and 10 mg/mL streptomycin. Cells were sub-cultured every 48–72 h at a
confluency of 80–90%. After confluent, HepG2 cells were exposed to PFBS with or without 300
μM fatty acid (FA) mixture conjugated by bovine serum albumin (oleic acid:palmitic acid = 2:1)
as an inducer of steatosis for 48 h (Dhami-Shah et al., 2018; Yang et al., 2019a). All treatments
included DMSO at a final concentration of 0.1%.
6.2.3

Measurement of cell viability

Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT)-based assay (Gerlier and Thomasset, 1986). HepG2 cells were seeded in a 96-well plate,
and cells were treated with PFBS at various concentrations for 2 days. The cells were then treated
with 5 mg/ml MTT at 37 °C for 4 h. Cell viability was then assessed by the formation of
formazan from MTT. The purple formazan was dissolved in DMSO and the absorbance at 540
nm was determined using a SpectraMax i3 microplate reader (Molecular Devices, Sunnyvale,
CA).
6.2.4

Triglyceride quantification

Triglyceride levels were determined using a commercial kit (Infinity™ Triglycerides Reagent).
Briefly, after 48 h, cells were washed twice with phosphate-buffered saline (PBS) and harvested
by scraping the cells from the culture plate in PBS containing 1% Triton-X. Cell homogenates
were obtained by sonication using Fisherbrand™ Model 50 Sonic Dismembrator (Fisher
Scientific), and TG concentrations were determined according to the manufacturer’s instructions.
Protein concentrations were measured using Pierce BCA Protein Assay Kit and used for
normalization of samples.
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6.2.5

Reverse transcriptase quantitative PCR (RT-qPCR) analysis

Total RNA was isolated from cells using TRIzol Reagent (Life Technologies, Carlsbad, CA)
according to manufacturer’s instruction. Conversion of total RNA to single stranded cDNA was
performed using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies,
Carlsbad, CA). Gene expression assays for sterol regulatory element-binding protein 1 (SREBP1,
Hs01088679_g1), acetyl-CoA carboxylase (ACC, Hs01046047_m1), fatty acid synthase (FAS,
Hs00236330_m1), peroxisome proliferator-activated receptor α (PPARα, Hs00947536_m1),
peroxisome proliferator-activated receptor γ (PPARγ, HsXXXXXX_m1), carnitine
palmitoyltransferase 1α (CPT1α, Hs00912671_m1), cluster of differentiation 36 (CD36,
Hs00354519_m1), diacylglycerol O-acyltransferase 2 (DGAT2, Hs01045913_m1) and DNA
damage-inducible transcript 3 (DDIT3, Hs00358796_g1) were performed with Taqman Universal
Master Mix II (Applied Biosystems, Carlsbad, CA) on a StepOne Plus Real Time PCR System
(Applied Biosystems, Carlsbad, CA). The results of target gene expression levels were
normalized to the expression level of the eukaryotic18S rRNA gene (Hs99999901_s1) using the
2-ΔΔCt method (Livak and Schmittgen, 2001).
6.2.6

Measurement of intracellular reactive oxygen species (ROS)

Intracellular ROS were measured by fluorescence dye 2′,7′-dichlorofluorescin diacetate
(DCFDA) assay as described (LeBel et al., 1992; Yang et al., 2018a). DCFDA was first dissolved
in DMSO and 25 μM DCFDA solution was freshly prepared in HEPES buffer. Cells were preincubated with DCFDA for 45 min at 37 °C. DCFDA was then replaced by PFBS treatment and
fluorescence was measured at excitation 485 nm and emission 535 nm at 1, 3, and 12 h after
treatment (SpectraMax i3, Molecular Devices LLC, San Jose, CA).
6.2.7

Measurement of cytosolic calcium

Cytosolic calcium levels were measured by cell permeate fluorescence dye, Fura-2acetoxymethyl ester (Fura-2 AM), using the ratiometric method (Roe et al., 1990; Yang et al.,
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2018a). The conformation of fluorescent dye changes when chelated with Ca2+, resulting in
change of excitation wavelength from 380 nm to 340 nm, but did not influence the emission
wavelength and 510 nm. Fura-2 AM was diluted in HEPES buffer containing 0.01% pluronic
acid. Before PFBS treatment, cells were pre-incubated with 2 μM Fura-2 AM for 60 min at room
temperature. Dye was then removed, and cells were incubated with HEPES buffer for another 30
min at room temperature for ester hydrolysis without the further compartmentation of Fura-2 AM
into intracellular organelles, for example ER. Cells were then treated with PFBS and cytosolic
calcium levels were estimated by the ratio of fluorescence intensities detected at emission 510 nm
with excitation wavelengths of 340 nm and 380 nm (510 nm/340 nm vs. 510 nm/380 nm)
(SpectraMax i3, Molecular Devices LLC, San Jose, CA).
6.2.8

Data Analysis

Data in Figures 1-7 were analyzed with two-way ANOVA. Data in Figures 8 were analyzed with
one-way ANOVA. Data in Figures 9 were analyzed with three-way ANOVA. All data were
analyzed using the Statistical Analysis System 9.3 (SAS Institute, Cary, NC). All data are
expressed as the mean ±standard error of the mean. Multiple comparisons among groups were
performed using Tukey’s test. P values less than 0.05 are reported as statistically significant. N is
defined as the number of replicates in each experiment.
6.3
6.3.1

Results
PFBS enhances fat accumulation in HepG2 cells
To investigate the effects of PFBS on fat accumulation in liver cells, HepG2 cells were

treated with PFBS with or without 300 µM fatty acid mixture conjugated by bovine serum
albumin (oleic acid:palmitic acid= 2:1, FA) as the inducer of steatosis. The cytotoxicity of PFBS
on HepG2 cells was first determined. As shown in Figure 6.1, there was no interaction between
FA and PFBS with respect to cell viability (P=0.0865). 300 µM FA treatment significantly
reduced the percentage of viable cell (P<0.0001). PFBS from 50 to 200 µM has no cytotoxic

64

effect on HepG2 cells with or without FA (P=0.1592). From these results, it was decided to use
PFBS concentrations up to 200 µM for the following experiments.

Figure 6.1 Cytotoxicity of PFBS in HepG2 hepatocytes. HepG2 cells in 96-well culture plates
were treated with PFBS (0, 50, 100, and 200 µM) with or without fatty acid mixture for 48 hours.
After 48 hours, cell viability was determined by MTT assay. Numbers are mean ±S.E. (n= 10).
Next, we investigated the role of PFBS in fat accumulation in hepatocytes (Figure 6.2).
As expected, FA treatment significantly elevated TG content (P<0.0001), with significant
interaction between PFBS and FA treatment (P=0.0023). After 48h treatment, our data showed
that PFBS at 200 µM supplemented with 300 µM FA significantly increases the fat accumulation
by 27% compared with FA control (P=0.0001). However, we observed no effects of PFBS
treatment without FA compared with control.
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Figure 6.2 PFBS promotes triglyceride accumulation in HepG2 cells. After treatment for 48
hours, hepatocytes were harvested and measured for triglyceride content that were normalized by
protein. Numbers are mean ±S.E. (n=4). Means with different letters are significantly different at
P< 0.05.
6.3.2

Effects of PFBS on lipogenesis pathways
To understand the role of PFBS in hepatic lipid metabolism, as well as the potential

interaction between PFBS and FA supplementation, we next tested whether PFBS treatment
could induce mRNA expression of lipogenesis-related genes in HepG2 cells with or without
induction of steatosis. Figure 6.3 shows the influence of PFBS exposure for 48 hours on the
expression levels of lipogenesis related genes. No interaction between PFBS and FA treatment
can be observed in the expression of these genes. FA treatment significantly increased the
expression levels of key genes in de novo fatty acid synthesis; acetyl-CoA carboxylase (ACC,
Figure 6.3A, 35%, P=0.0453), fatty acid synthase (FAS, Figure 6.3B, 42%, P=0.0038), and sterol
regulatory element-binding protein 1 (SREBP1, Figure 6.3C, 39%, P=0.0446), while
diacylglycerol acyltransferase 2 (DGAT2), a key regulator in TG synthesis expression, was not
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affected by FA treatment (Figure 6.3D, P=0.4531). Treatment with 200 µM PFBS significantly
enhanced the mRNA expression levels of ACC (Figure 6.3A, 75%, P=0.0014), FAS (Figure
6.3B, 98%, P<0.0001), and SREBP1 (Figure 6.3C, 74%, P=0.0028), as well as DGAT2 (Figure
6.3D, 39%, P=0.0008).

Figure 6.3 Effects of PFBS on lipogenesis gene expression in HepG2. Cells were treated with
PFBS (200 µM) and FA (300 µM) for 48 hours. mRNA levels of indicated genes were quantified
by RT-qPCR and the ∆∆Ct was determined using eukaryotic 18S rRNA as a housekeeping gene.
FAS, fatty acid synthase (A); ACC, acetyl-CoA carboxylase (B); SREBP1, sterol regulatory
element-binding protein 1 (C); DGAT2, diglyceride acyltransferase 2 (D). Numbers are mean ±
S.E. (n=4).
6.3.3

Effects of PFBS on fatty acid uptake pathways
Besides lipogenesis pathways, the uptake of circulating free fatty acid also plays an

important role in the accumulation of hepatic lipid (Vergani, 2017). Therefore, we next
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investigated the potential effects of PFBS on fatty acid translocase (FAT/CD36), a major lipid
trafficking gene, and peroxisome proliferator-activated receptor gamma (PPARγ), its major
regulator (Huck et al., 2018; Wan et al., 2012). Similar to the results for lipogenesis related genes,
no significant interaction between PFBS and FA can be observed. FA treatment significantly
promoted the expressions of these genes (CD36, 47%, P=0.0019; PPARγ, 45%, P=0.0036), while
PFBS significantly increased the expressions of CD36 (Figure 6.4A, 26%, P=0.0012) and PPARγ
(Figure 6.4B, 47%, P=0.0032).

Figure 6.4 Effects of PFBS on fatty acid uptake gene expression in HepG2. Cells were treated
with PFBS (200 µM) and FA (300 µM) for 48 hours. mRNA levels of indicated genes were
quantified by RT-qPCR and the ∆∆Ct was determined using eukaryotic 18S rRNA as a
housekeeping gene. PPARγ, peroxisome proliferator-activated receptor gamma (A); CD36, fatty
acid translocase (B). Numbers are mean ±S.E. (n=4).
6.3.4

Effects of PFBS on PPARα and CPT1α
The inhibition of mitochondrial β oxidation could be another potential mechanism in the

accumulation of TG. In order to verify the role of mitochondrial β oxidation in the effects of
PFBS on TG accumulation, we next investigated whether PFBS exposure could affect the
expression of carnitine palmitoyltransferase 1 alpha (CPT1α), the key regulator of β oxidation, as
well as its upstream regulator, peroxisome proliferator activated receptor alpha (PPARα). In the
present study, neither interaction nor FA effects can be observed on the expression of these genes.
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On the other hand, PFBS significantly induced the expressions of PPARα (Figure 6.5A, 67%,
P=0.0019), and CPT1α (Figure 6.5B, 149%, P=0.0002).

Figure 6.5 Effects of PFBS on fatty acid oxidation gene expression in HepG2. Cells were treated
with PFBS (200 µM) and FA (300 µM) for 48 hours. mRNA levels of indicated genes were
quantified by RT-qPCR and the ∆∆Ct was determined using eukaryotic 18S rRNA as a
housekeeping gene. PPARα, peroxisome proliferator-activated receptor alpha (A); CPT1α,
carnitine palmitoyltransferase 1 alpha (B). Numbers are mean ±S.E. (n=4).
6.3.5

Effects of PFBS on ROS, ER stress pathways, and cytosolic calcium
Next, we examined how PFBS could affect the production of reactive oxygen species

(Figure 6.6), which is also a potential mechanism of liver steatosis (Masarone et al., 2018). Thus,
effects of PFBS on ROS production after 1, 3, and 12-hour treatment of PFBS were investigated.
Among the three time points, significant interactions between PFBS and FA were observed only
at 3 hours (P=0.0009) and 12 hours (P<0.0001); while the PFBS treatment effect was observed
independent of the FA effect at 1 hour. FA significantly increase ROS at all time points (1 hour,
179%, P<0.001; 3 hours, 248%, P<0.001; 12 hours, 187%, P<0.001). Also, significant increases
can be observed on ROS production after treatment of PFBS for 1, 3, and 12 hours (1 hour, 18%,
P<0.001; 3 hours, 30%, P<0.001; 12 hours, 59%, P<0.001).
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Figure 6.6 Effects of PFBS on reactive oxygen species (ROS) production in HepG2. HepG2 cells
were preincubated with 25 μM DCFDA as ROS probe and treated with PFBS (200 µM) and FA
(300 µM), and ROS levels were measured at 1, 3, and 12 hours. Numbers are mean ±S.E. (n=6).
Means with different letters are significantly different at P< 0.05.
Endoplasmic reticulum (ER) stress results from the unfolded protein response (UPR)
induced by accumulation of misfolded or unfolded protein in ER, which is also one of the
modulators in lipogenesis (Lebeaupin et al., 2018). Besides, ER stress is largely connected to the
production of ROS, as ER accounts for 25% of total cellular ROS generation (Shimizu and
Hendershot, 2009). CCAAT/enhancer-binding homologous protein (CHOP), one of the key
markers in ER stress, is also responsible for the UPR-mediated ROS generation (van Galen et al.,
2014). Thus, we tested whether PFBS treatment could affect CHOP. As shown in Figure 6.7,
interaction was not found between PFBS and FA treatment on CHOP expression. Increased
expression of CHOP can also be observed after FA treatment (23%, P=0.0446), while PFBS
significantly increased the transcript level of CHOP (82%, P<0.0001).
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Figure 6.7 Effects of PFBS on ER stress pathway in HepG2. Cells were treated with PFBS (200
µM) and FA (300 µM) for 48 hours. mRNA levels of indicated genes were quantified by RTqPCR and the ∆∆Ct was determined using eukaryotic 18S rRNA as a housekeeping gene. CHOP,
C/EBP homologous protein. Numbers are mean ±S.E. (n=4).
As calcium homeostasis is crucial in hepatic lipid metabolism, and it is intertwined with
oxidative stress and ER stress (Bahar et al., 2016; Berridge et al., 2003; Brookes et al., 2004),
here we also investigated the effect of PFBS on cytosolic calcium (Figure 6.8). As a result, 200
µM PFBS treatment for 1 hour significantly increased the cytosolic calcium by 17% (P=0.0278).
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Figure 6.8 Effects of PFBS on cytosolic calcium in HepG2. HepG2 cells were pre-treated with 2
μM Fura-2 AM, and then treated with PFBS (200 µM). Cytosolic calcium was measured after 1
hour. Numbers are mean ±S.E. (n=6). * indicates a significant difference against the respective
control (P< 0.05)
6.3.6

PFBS promotes fat accumulation in HepG2 cells via PPARγ mediated pathway
PPARγ is the one of key regulators modulating lipid metabolism in liver regulating both

lipogenesis and FA uptake (Schadinger et al., 2005; Zhou et al., 2008). We further investigated
whether the promoted accumulation of fat caused by PFBS is mediated by the activation of
PPARγ. To determine whether the effect of PFBS is PPARγ-mediated, GW9662 (an antagonist of
PPARγ) was used to determine if the inhibition of PPARγ could reverse the promoted hepatic fat
accumulation induced by PFBS. HepG2 cells were exposed under the combination treatment of
200 µM PFBS, 300 µM FA, and 40 µM GW9662. Since there was significant three-way
interaction among PFBS, FA, and GW9662, all treatment groups were compared separately
(Figure 6.9). PFBS increased the TG content with or without the addition of FA by 18% and 28%,
although the increase in non-FA group is insignificant. However, with the addition of GW9662,
the increases induced by PFBS were eliminated both with and without FA. These results
suggested that PFBS promotes fat accumulation via a PPARγ-dependent pathway.
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Figure 6.9 Increase in triglyceride accumulation caused by PFBS were abolished by GW9662.
Cells were treated with PFBS (200 µM), FA (300 µM), and GW9662 (40 µM). After treatment
for 48 hours, hepatocytes were harvested and measured for triglyceride content that were
normalized by protein. Numbers are mean ±S.E. (n=4). Means with different letters are
significantly different at P< 0.05.
6.4

Discussion
The liver is known as the major site for regulating lipid in the body, playing a crucial role

in normal lipid homeostasis. In the current study, we demonstrated that PFBS increased fat
accumulation in HepG2 hepatocytes. We further investigated the effects of PFBS on hepatic lipid
metabolism, as well as its interaction with FA. It was also found that PFBS may trigger oxidative
stress, ER stress, and the impairment in calcium homeostasis. Finally, the increase hepatic fat
accumulation was mediated in part by PPARγ regulated pathway.
PPARγ is the master regulator of whole-body lipid metabolism. PPARγ is most highly
expressed in adipose tissue, where it regulates the adipocyte differentiation (Siersbæk et al.,
2010). In addition, PPARγ is also well known to promote hepatic steatosis. Indeed, hepatic
PPARγ expression is increased in the mice with high-fat-diet induced steatosis (Inoue et al.,
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2005). The overexpression of hepatic PPARγ has been reported to induce steatosis by activating
lipogenesis genes, ACC, FAS, and SREBP1 (Schadinger et al., 2005; Yu et al., 2003), and free
fatty acid uptake transporter, CD36 (Zhou et al., 2008). In this study, PFBS significantly elevated
the expression of PPARγ (Figure 6.4A), and genes regulating lipogenesis (Figure 6.3) and FA
uptake (Figure 6.4B) were both activated by PFBS treatment. Also, the current results suggested
that the effect of PFBS on increased fat accumulation is dependent on the activation of PPARγ
(Figure 6.9). As shown in Figure 6.2, effect of PFBS on TG accumulation was enhanced when
FA is available in the media, which implies an important role of PPARγ/CD36-mediated FA
uptake in the effects of PFBS. Consistent with our finding, in a recent study using liver-specific
PPARγ knockdown model, CD36-mediated FA uptake was reported to be the major target of
hepatic PPARγ in steatosis, while genes regulating de novo lipogenesis and TG synthesis,
including ACC, FAS, SREBP1, and DGAT2, were not affected by the knockdown of PPARγ
specifically in liver (Wolf Greenstein et al., 2017). Thus, PFBS appears to activate PPARγ, which
mainly promotes FA uptake and leads to increased hepatic fat accumulation. However, although
PFBS has been reported to activate human PPARγ, the activation potency was relatively low
compared with PFOS (Zhang et al., 2014). Based on the current data, it remained unclear whether
the activation of PPARγ is induced directly by the exposure to PFBS, or it is induced by the
upstream effectors.
Besides PPARγ, PPARα is a known target for PFAS, including PFBS (Wolf et al., 2008).
Previous studies have suggested the upregulation of key enzymes in fatty acid β oxidation,
including CPT1α, upon PFOS exposure in rodents (Wan et al., 2012), which is regulated by the
activation of PPARα (Song et al., 2010). However, another study on PPARα-null mice revealed
the PPARα-independent effects of PFOS (Rosen et al., 2010). In the current study, as expected,
PFBS significantly activated the expression of both PPARα and CPT1α (Figure 6.5). However,
since FA are ligands of PPARs (Grygiel-Górniak, 2014), it is possible that the hepatic
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accumulation of FA might activate PPARα and subsequently CPT1α, which is the secondary
effect of PFBS-induced fat accumulation. Therefore, although mitochondrial β oxidation was
activated by PFBS treatment, it might not be relevant to the fat accumulation induced by PFBS.
On the other hand, mitochondrial β-oxidation could be a source of the increased ROS
production. The increased amounts or activities of fatty acid oxidation enzymes have been
reported to be associated with the net production of ROS in liver (Tahara et al., 2009). Besides,
accumulating evidences have supported the strong connections between oxidative stress and ER
stress. The primary function of ER is folding and assembling proteins, but its function can be
disrupted when the cells are under stress, for example lipid overload. Unfolded and misfolded
proteins can accumulate in ER lumen and activate unfolded protein response (UPR) (Malhotra
and Kaufman, 2007). A prolonged ER stress and UPR can result in excessive production of ROS
by the activation of CHOP (van Galen et al., 2014). The protein folding process is also dependent
largely on the redox homeostasis. Oxidative stress could potentially interfere the protein folding
process, which generates misfolded or unfolded protein, and subsequently ER stress (van der
Vlies et al., 2003). Besides, oxidative stress and ER stress can also be mediated by the imbalance
of calcium. The increased level of cytosolic calcium could lead to the activation of ER stress
(Bahar et al., 2016; Berridge et al., 2003). On the other hand, increased metabolic rate caused by
increased calcium results in increased respiratory chain electron leakage and ROS production
(Brookes et al., 2004). From the current data, significant increases in ROS production (Figure
6.6), CHOP expression (Figure 6.7), and cytosolic calcium (Figure 6.8) were identified, which is
consistent with the studies on PFOS, the higher molecular weight cognate of PFBS (Eriksen et al.,
2010; Liu et al., 2011; Oh et al., 2017; Qian et al., 2010). Therefore, it is possible that PFBS
could potentially induce hepatic fat accumulation through the activation of oxidative stress, ER
stress, and calcium imbalance. However, the interaction between these factors on PFBS-induced
fat accumulation is needed to be further investigated.
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PFBS is generally believed to be less toxic than PFOS due to its shorter biological halflife in human (~1 month). A 7 μg/L (23 nM) health risk limit in groundwater for PFBS was
established in Minnesota, and the EPA has set a sub-chronic reference dose of 0.2 mg/kg/d and
chronic reference dose of 0.02 mg/kg/d (EPA, 2014). The no-observed-adverse-effect level
(NOAEL) for PFBS was determined to be 60 mg/kg/d for males and 600 mg/kg/d for females in
rats after a 90-day oral study (Lieder et al., 2009). The levels of PFBS in the liver after single or
repeated oral dose have been reported in rats and mice. In Sprague-Dawley rats, liver PFBS
concentration at day 4 after a single dose of 30 mg/kg was 0.45 μmol/kg for male and 1.14
μmol/kg for female (Olsen et al., 2009a). In male C57BL/6 mice exposed to 16 mg/kg/d of 35Slabeled PFBS for 3 days, 35S labeled PFBS was found to distribute to the liver at 31 μmol/kg,
being as much as 1.6-fold the level in blood (19 μmol/kg), suggesting a potential accumulation in
the liver (Bogdanska et al., 2014). In human, serum PFBS levels of factory workers have been
found to be approximately 23 ng/ml (77 nM) (Fu et al., 2015). Given this limited data set, the
doses used in the current study may not be achievable. Nevertheless, the effects of obesogens can
be aggravated by dietary fat intake as previous studies have shown the interaction between
obesogens treatment and dietary fat (Sun et al., 2017; Sun et al., 2016b; Xiao et al., 2017a; Xiao
et al., 2018). Therefore, despite the high concentration used in this study, the effects of PFBS on
hepatic fat accumulation could elucidate a potential risk on the development of NAFLD.
6.5

Conclusion
In conclusion, this study investigated the effects of PFBS, a replacement of PFOS, on

hepatic lipid metabolism, as well as its interaction with FA overloads. Potential link between
PFBS exposure, high fat diet, and the risk of developing NAFLD was elucidated. The current
results, however, are limited to an in vitro model with relatively high concentrations of treatment.
Further well-designed studies in animals, as well as epidemiology studies, are needed to confirm
the current results.
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CHAPTER 7
Concluding Remarks
The incidence of metabolic diseases associated with disrupted lipid metabolisms, including
obesity, and non-alcoholic fatty liver disease (NAFLD), have been increasing in the last few
decades. Western diet, sedentary lifestyle, and genetic profile have been associated with the
pathogenesis of these diseases. However, the dramatic increases cannot be completely explained
by these contributing factors. Recently, accumulating literatures have elucidated the potential
connections between environmental contaminants and the development of obesity and NAFLD
(Arciello et al., 2013; Armstrong and Guo, 2019; Wang et al., 2016). However, there is a big
knowledge gap on the potential mechanisms of these effects. Thus, the objective is to clarify the
mechanisms of altered lipid metabolism in adipocytes and hepatocytes induced by environmental
contaminants (ivermectin and PFBS). By understanding molecular mechanisms by which
exposure to environmental contaminants may induce or prevent the development of obesity and
type 2 diabetes, we will be able to direct more efficient prevention and/or treatment strategies for
these and related pathologies in the future.
Ivermectin, a member of the avermectins, is one of the most extensively used antiparasitic agents worldwide, and acts by binding to glutamate-gated chloride channels in
invertebrate nerve cells. There is limited information, however, on the effects of ivermectin in
non-neural cell, such as mammalian adipocytes. Our current study aimed to investigate the role of
ivermectin in adipogenesis using 3T3-L1 preadipocytes. From our data, ivermectin inhibited the
differentiation of preadipocytes and TG accumulation. In particular, the effects of ivermectin was
found to focus on middle to late stage of the differentiation. Ivermectin treatment also
significantly reduced the mRNA expression of key markers in adipogenesis, modulated the
expression of genes regulating fatty acid synthesis, uptake, and oxidation, and enhanced the gene
expression of two subunits of the glycine receptor (GlyR). Specifically, the protein levels of
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peroxisome proliferator-activated receptor gamma (PPARγ), CCAAT/enhancer-binding protein
alpha (C/EBPα), and acetyl-CoA carboxylase (ACC) were reduced by ivermectin treatment. Of
interest, the suppression of TG accumulation by ivermectin was partially abolished by
rosiglitazone, a specific PPARγ agonist, but Z-guggulsterone, a selective FXR antagonist, failed
to rescue the ivermectin-induced effect on adipogenesis. Lastly, ivermectin prevented
adipogenesis induced by permethrin and fipronil.
PFBS is used as the replacement of PFOS since 2000 because of the concern on PFOS’
persistence in the environment and the bioaccumulation in animals. Accumulating evidence has
shown the correlation between the exposure to perfluorinated compounds and enhanced
adipogenesis. There is no report, however, of the effect of PFBS on adipogenesis. Here, we
investigated the role of PFBS in adipogenesis using 3T3-L1 adipocytes. PFBS treatment
extensively promoted the differentiation of 3T3-L1 preadipocytes to adipocytes. In particular, the
treatments of PFBS at the early adipogenic differentiation period (day 0-2) were positively
correlated with increased the triglyceride accumulation on day 6. PFBS treatments significantly
increased the protein and mRNA levels of the master transcription factors in adipocyte
differentiation; C/EBPα and PPARγ, along with ACC and FAS, the key proteins in lipogenesis.
PFBS significantly activated the phosphorylation of extracellular signal-regulated kinase1/2
(ERK1/2) after 4-hour treatment, and PFBS' effect on triglyceride was abolished by U0126, a
specific MAPK/ERK kinase (MEK) inhibitor.
To elucidate the potential role of PFBS on the development of NAFLD, we next
investigated the effects of PFBS on hepatic lipid metabolism using HepG2 cells as model. PFBS
treatment for 48 hours significantly increased the triglyceride level with fatty acid (FA) mixture
(oleic acid:palmitic acid = 2:1), but not without FA. Moreover, the expression levels of genes
regulating lipogenesis were enhanced by PFBS treatment. PFBS also induced hepatic FA uptake
implied by the upregulation of key genes modulating the capacity of FA trafficking to liver.
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PFBS' effect on triglyceride was abolished by GW9662, a specific peroxisome proliferatoractivated receptor gamma (PPARγ) antagonist. Besides, PFBS treatment also promoted the
production of reactive oxygen species (ROS), endoplasmic reticulum (ER) stress marker and
cytosolic calcium.
Collectively, environmental contaminants (ivermectin and PFBS) interrupt lipid
metabolisms in adipose tissue and liver with different mechanisms. With further study on animals
or humans, our results might provide some insights for the design of strategies against the
development of diseases associated with lipid metabolisms.
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